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The Immunopathology of Sepsis: Pathogen Recognition, Systemic
Inflammation, the Compensatory Anti-Inflammatory Response, and
Regulatory T Cells
D.H. Lewis, D.L. Chan, D. Pinheiro, E. Armitage-Chan, and O.A. Garden
Sepsis, the systemic inflammatory response to infection, represents the major cause of death in critically ill veterinary
patients. Whereas important advances in our understanding of the pathophysiology of this syndrome have been made,
much remains to be elucidated. There is general agreement on the key interaction between pathogen-associated molecular
patterns and cells of the innate immune system, and the amplification of the host response generated by pro-inflammatory
cytokines. More recently, the concept of immunoparalysis in sepsis has also been advanced, together with an increasing
recognition of the interplay between regulatory T cells and the innate immune response. However, the heterogeneous nat-
ure of this syndrome and the difficulty of modeling it in vitro or in vivo has both frustrated the advancement of new thera-
pies and emphasized the continuing importance of patient-based clinical research in this area of human and veterinary
medicine.
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Sepsis, defined as the systemic inflammatoryresponse to infection (Box 1), remains the major
cause of death in critically ill human patients.1–6
Recent human studies estimate the annual incidence of
sepsis to be 240–300 cases per 100,000 population,
with associated costs of nearly $17 billion in the Uni-
ted States7,8; the rate of occurrence is also increasing
at around 9% each year.8 Although large-scale veteri-
nary epidemiological studies are uncommon, a sub-
stantial proportion of the critically ill veterinary
population is estimated to be septic.9,10 The case fatal-
ity rate associated with sepsis in a variety of veterinary
species is reported to approach 50%, emphasizing the
need for a greater understanding of the pathophysiol-
ogy of sepsis to improve therapeutic practices.11–13
The pathophysiology of sepsis remains incompletely
understood. A multitude of cell types, inflammatory
mediators, and coagulation factors are involved and
recent research has focused on the contributions of the
innate immune system and T cells in this complex syn-
drome.2,14–20 This review will present an account of
the current understanding of the function of the
immune system in sepsis, with emphasis on the interac-
tion of pathogens with innate components of the
immune system and the key role of the endothelium in
triggering and propagating a pro-inflammatory state.
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Abbreviations:
AGE advanced glycation end product
AP-1 activator protein 1
aPC activated protein C
BK bradykinin
CARD common caspase activation and recruitment domain
CLARP caspase-like apoptosis regulatory protein
DAMP danger-associated molecular pattern
gp glycoprotein
HMBG high mobility group box protein
HSP heat shock protein
Ig immunoglobulin
IKK inhibitor of j B kinase
IPAF interleukin-1 converting enzyme (ICE) protease-
activating factor
IPS-1 interferon-b promoter stimulator-1 (also known as
CARD adaptor inducing interferon-b [Cardif])
IRAK IL-1R associated kinase
IRF interferon regulatory factor
KK kallikrein
LDL low density lipoprotein
LGP2 laboratory of genetics and physiology 2
MAPK mitogen-activated protein kinase
MDA5 melanoma differentiation-associated gene 5
MODS multiple organ dysfunction syndrome
MyD88 myeloid differentiation primary response gene 88
NAIP neuronal inhibitor of apoptosis
NEMO NF-jB essential modulator
NF-jB nuclear factor kappa B
NLR nucleotide-binding domain, leucine-rich repeat
containing protein
NLRB NLR family, baculovirus inhibitor of apoptosis
protein repeat domain containing
NLRC NLR family, CARD containing
NLRP NLR family, pyrin domain containing
NOD nucleotide-binding oligomerization domain
PAMP pathogen-associated molecular pattern
PAR protease-activated receptor
PMN polymorphonuclear cell
PRR pattern-recognition receptor
RAGE receptor for advanced glycation end products
RICK RIP-like interacting CLARP kinase
RIG-1 retinoic acid-inducible gene-1
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Box 1
Definitions of SIRS, sepsis, and MODS1,4,6
SIRS (systemic inflammatory response syndrome):
clinical manifestation of the systemic response to injury.
Sepsis: SIRS in association with bacterial, viral, proto-
zoal or fungal infection.
Severe sepsis: sepsis together with evidence of organ
dysfunction, hypoperfusion, or hypotension.
Septic shock: sepsis with hypotension despite adequate
fluid resuscitation.
MODS (multiple organ dysfunction syndrome): altered
organ function in an acutely ill patient such that
homeostasis cannot be maintained.
In addition, the complex interplay between pro- and anti-
inflammatory cytokines and the spectrum of the host
defense response will be discussed. Finally, the impor-
tance of regulatory T cells (Tregs) in maintaining the bal-
ance of host inflammatory mechanisms will be described.
Immunopathology of Sepsis
Living organisms face a constant barrage of poten-
tially pathogenic microorganisms. Survival depends
upon physical barriers to resist entry of pathogens, as
well as the presence of a constitutive, or innate,
immune system that can rapidly induce a defensive
inflammatory response. Such a system can be found in
virtually all species, suggesting that it is evolutionarily
ancient and highly successful.21,22 The innate immune
system further interacts with the adaptive immune sys-
tem, based on a system of T and B lymphocytes that
respond to specific epitopes.
Surface Barrier Mechanisms and Antimicrobial
Peptides
Whereas the keratinized epithelium of the dermis
and the mucous lining of the body cavities discourage
pathogenic colonization, various other innate defenses
are employed to minimize penetration of the body
wall by microorganisms, including antimicrobial
peptides (AMPs; otherwise known as host-defense
peptides) on mucosal surfaces.23,24 A comprehensive
review of AMPs in veterinary species has recently
been published.25 In summary, AMPs comprise 3
main groups: digestive enzymes and peptides that dis-
rupt the microbial cell membrane, peptides that bind
essential elements, and peptides that act as decoys for
microbial attachment. The 2 major classes of bacteri-
cidal AMPs in the mammalian immune system are
the defensins and cathelicidins. Compared to eukary-
otic cells, bacterial cell walls lack cholesterol—which
acts to stabilize cell membranes—and negatively
charged phospholipids. Instead, bacterial cell walls are
rich in anions (basic amino acids) and thus attract
the cationic defensins, which carpet the microbial
membrane and institute channel formation.26 These
channels then lead to transmembrane pore formation,
membrane destabilization, and microbial cell death,
although recent studies suggest that their function
could go beyond that of lipid bilayer perturbation.27
Whereas a large number of AMPs form part of the
non-oxidative killing mechanism within phagolyso-
somes in cells such as neutrophils and macrophages,
a growing number are thought to be actively secreted
onto epithelial surfaces of the gastrointestinal, respira-
tory and urinary tracts28–31—including the ovine gas-
trointestinal tract32 and the canine testis.33 Recent
work has revealed that important amounts of these
AMPs are secreted not only by immune cells such as
neutrophils and alveolar macrophages but also by
atypical defense cells such as type II pneumocytes.34
This theme is universal throughout the processes of
the innate immune system and challenges the tradi-
tional view of a “standing army” of immune defense
cells, replacing it with the concept of a body-wide,
integrated community of cells contributing to patho-
gen vigilance.35
Recognition of Pathogens: PAMPs, MAMPs and
DAMPs
Two factors are vital to the rapid ability of the
innate immune system to respond to pathogen incur-
sion: the presence of receptors against pathogen mark-
ers and the ubiquitous nature of these receptors in the
body.35 Individual receptors are genetically encoded
and display strong homology within and between spe-
cies.22 These receptors are not only expressed on many
effector cells of the immune system—including macro-
phages, neutrophils, dendritic cells, and lymphocytes—
but are also found on epithelial cells, endothelial cells,
and myocytes36,37; expression has also been detected in
the bovine endometrium.38 The major targets of these
pattern recognition receptors (PRRs) are known as
pathogen-associated molecular patterns (PAMPs),
although the presence of these molecules in nonpatho-
genic and commensal bacteria has led to the sugges-
tion that the term “microbial-associated molecular
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patterns” (MAMPs) is more accurate. These molecules
share certain core characteristics:
• PAMPs are produced only by microbial patho-
gens, not by the host (eg, peptidoglycans are
produced by bacteria but not by eukaryotic cells):
this confers automatic self/nonself discriminatory
ability.
• PAMPs are generally invariant molecules shared
by entire classes of microorganisms (eg, lipoarabi-
nomannan is found on the cell wall of all Myco-
bacteria); this allows the evolutionary retention of
a relatively small number of PRRs recognizing
vast numbers of potential pathogens.
• PAMPs are usually structures vital to the survival
or pathogenicity of the microorganism (eg, lipo-
polysaccharide [LPS] in the outer membrane of
Gram-negative bacteria): this allows targeting of
highly conserved molecules and obviates the need
for variability in host PRRs.
Although bacterial cell surface components such as
LPS in the outer cell membrane of Gram-negative bac-
teria and lipotechoic acid (LTA) in the cell membrane
of Gram-positive bacteria represent classic examples of
PAMPs, recognition of “altered self” secondary to
host cell colonization by viral pathogens is also likely.
The innate immune system has thus developed the
ability to detect markers of endogenous cell damage
called “alarmins” or “danger-associated molecular pat-
terns” (DAMPs)39–41 Table 1 shows key PAMPs and
their corresponding receptors,42,43 whereas Table 2
shows some of the confirmed interactions of
DAMPs.39,40,43–46 Nonrodent sepsis models, genetic
approaches, and immunological studies have demon-
strated the presence of a large number of PRRs in
clinical veterinary species (Table 3).38,47–55
Initiation of an inflammatory reaction to necrotic,
rather than apoptotic, cell death would appear to be
useful in host defense; however, the interaction of
DAMPs and PAMPs with their receptors leads to
increased case fatality rates in sepsis.15,19,56 Owing to
PRR cross-reactivity for both PAMPs and DAMPs,
multiple positive feedback systems become established,
leading to rapid progression of a global inflammatory
response with consequent clinical signs (Fig 1).16,19,57
Functional interactions between PRRs, including syn-
ergy and cross-tolerance, also occur.58,59 If an inflam-
matory state persists, the very defensive mechanisms of
the innate immune system designed to protect the host
can lead to further tissue damage, as well as dimin-
ished antimicrobial activity that allows opportunistic
secondary infections.15,20 Whereas the existence of such
feedback systems in veterinary species can at present
only be inferred, experimental data suggest PRR reac-
tivity to both pathogen- and host-derived ligands in
cattle, pigs, horses, and dogs.60–66 Furthermore, the
blunted PAMP-induced TNF, IL-6 and IL-10 response
of whole blood in dogs with lymphoma is thought to
underlie their higher risk of sepsis.67
Table 1. Key pathogen-associated molecular pattern ligands of the pattern recognition receptors implicated in
sepsis.
PRR Location Cell Type PAMP Recognized
TLR 1/CD281 pm pbmc, np, u triacyl lipopeptide
TLR 2/CD282 pm, el pbmc, dc, mc, nkc peptidoglycan, lipoprotein, lipopolysaccharide,
glycosylphosphatidylinositols, mannans
TLR 3/CD283 pm, el dc, epi, fb, blc, nkc ssRNA, dsRNA, dsDNA
TLR 4/CD284 pm pbmc, mc, np, epi lipopolysaccharide, glycosylphosphatidylinositols,
viral envelope proteins, mannans
TLR 5 pm pbmc, dc, epi, nkc flagellin
TLR 6/CD286 pm mc, blc diacyl lipopeptide
TLR 7 el pbmc, dc, blc ssRNA
TLR 8/CD288 el nkc ssRNA
TLR 9/CD289 el dc, blc, nkc, epi ssDNA, dsDNA
TLR 10/CD290 pm pbmc, dc, blc Unknown
TLR 11 pm epi, dc, pbmc profilin
NOD1/NLRC1 cyt, pm epi, dc, pbmc peptidoglycan
NOD2/NLRC2/CARD15 cyt, pm epi, dc, pbmc, Paneth cells muramyl dipeptide
NLRC4/IPAF cyt unknown flagellin
NLRP1 cyt unknown muramyl dipeptide, Bacillus anthracis lethal toxin
NLRP3 cyt unknown bacterial & viral RNA, lipopolysaccharide, lipotechoic acid,
muramyl dipeptide
NLRB1/NAIP5 cyt unknown flagellin
PRR, pattern-recognition receptor; PAMP, pathogen-associated molecular pattern; TLR, Toll-like receptor; NOD, nucleotide-binding
oligomerization domain; NLR, nucleotide-binding domain, leucine-rich repeat containing protein; NLRC, NLR family, CARD contain-
ing; IPAF, interleukin-1 converting enzyme (ICE) protease-activating factor; NLRP, NLR family, pyrin domain containing; NLRB,
NLR family, baculovirus inhibitor of apoptosis protein repeat domain containing; NAIP, neuronal inhibitor of apoptosis; pm, plasma
membrane; el, endolysosomes; cyt, cytoplasma; np, neutrophils; u, ubiquitous; dc, dendritic cells; mc, mast cells; nkc, natural killer cells;
epi, epithelial cells; fb, fibroblasts; blc, B lymphocytes; ss, single-stranded; ds, double-stranded.
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Pattern Recognition Receptors: an Overview
Evolutionary pressure has resulted in the encoding of
a number of different host proteins within three distinct
families—the Toll-like receptors (TLRs), the nucleo-
tide-binding domain, leucine-rich repeat containing
proteins (NLRs; previously designated as the nucleo-
tide-binding oligomerization domain [NOD]-like receptors)
and the retinoic acid-inducible gene-1 (RIG-1)-like
receptors (RLRs).68–70 Cooperation between the RLRs—
intracellular viral nucleic acid sensors—and the
endosomal TLRs appears likely,71–73 although little is
currently known about the involvement of RLRs in the
pathogenesis of sepsis.14 This family of PRRs is there-
fore not considered further in this review.
Whereas PRRs form a heterogenous group of pro-
teins, certain characteristics—such as leucine-rich
repeat domains, scavenger receptor cysteine-rich
domains, and C-type lectin domains—can be com-
monly recognized.68,69
The Toll-Like Receptors
The Toll gene was first identified in Drosophila
melanogaster as encoding a transmembrane glycopro-
tein with a role in determination of dorsoventral
polarity in the embryo.74 Additional investigation
revealed a large extracellular component with leucine-
rich repeats, with a cytoplasmic portion described as
the TIR (Toll/interleukin-1 receptor [L-1R]) domain
owing to its similarity to the intracellular region of
the mammalian IL-1R.75 Not only was the Toll pro-
tein discovered to play a role in the innate immune
response to fungal infection in Drosophila, but a sub-
sequent series of studies served to highlight the link
between TLRs and the mammalian immune
response.76–79 To date, 10 human and 12 murine
functional TLRs have been identified by a combina-
tion of immunological techniques and examination of
genetic databases.42,71
The cytoplasmic TIR domain of the TLRs interacts
with a variety of TIR-domain-containing adaptors
(Fig 2).80–83 PAMP/DAMP ligation of the respective
PRR activates a chain of kinases in the IL-1R associ-
ated kinase (IRAK) family, ultimately resulting in
activation of the inhibitor of j B kinase (IKK) enzyme
complex and the mitogen-activated protein kinase
(MAPK) pathway (Fig 2).84–86 Whereas the connection
of TLR activation to the NF-jB and MAPK signaling
pathways is well recognized, a number of other path-
ways are also triggered by TLR stimulation, including
Protein Kinase R/eukaryotic translation initiation
Table 2. Key danger-associated molecular pattern ligands of the pattern recognition receptors.
PRR Location Cell Type DAMP Recognized
TLR 2/CD282 pm, el pbmc, dc, mc, nkc HMGB 1, necrotic cells, HSP-60, HSP-70, gp-96, biglycan, defensins
TLR 3/CD283 pm, el dc, epi, fb, blc, nkc endogenous mRNA
TLR 4/CD284 pm pbmc, mc, np, epi HSP-22, HSP-70, HSP-90, fibronectin, fibrinogen, heparan fragments,
hyaluronate fragments, b-defensin 2, oxidized LDL, surfactant
protein A, neutrophil elastase, HMGB 1, biglycan
TLR 9/CD289 el dc, blc, nkc, epi chromatin-IgG complex
NLRP3 cyt unknown uric acid crystals
RAGE pm u? AGEs, HMGB 1, amyloid peptide, S100s
New abbreviations (for previous abbreviations see Table 1): DAMP, danger-associated molecular pattern; RAGE, receptor for
advanced glycation end products; HMGB, high mobility group box protein; HSP, heat shock protein; gp, glycoprotein; LDL, low den-
sity lipoprotein; Ig, immunoglobulin; AGEs, advanced glycation end products; S100s, S100 proteins (calgranulins).
Table 3. Pattern-recognition receptors of those fami-
lies implicated in sepsis identified in veterinary species
to date.
Species TLRs NLRs
Dog 1–7, 9 NOD1, NOD2, NLRC4
NLRP 1–3, 5, 6, 8–10, 12–14
Cat 2–5, 7–9
Horse 2–4, 6, 9 NLRC4
Cow 1–10 NOD1, NOD2, NLRC4
NLRP 1, 3, 5, 6, 8–10, 12–14
Sheep 1–10 NOD2
Goat 1–10
Pig 1–10 NOD1, NOD2
For abbreviations, see footnote to Table 1.
Table 4. The spectrum of type I and type II acute
phase proteins.
Acute Phase
Protein Role Type
Serum
amyloid A
Leukocyte recruitment
and activation
I – induced by
IL-1 and TNF
C-reactive protein Enhance microbial
phagocytosis and
complement binding
C3, C4, C4BP,
C1inh
Complement
components
Haptoglobin (rat) Binds free hemoglobin
a1-acid
glycoprotein
Transport functions
Fibrinogen Hemostasis II – induced by
IL-6 and IL-6-like
cytokines
Haptoglobin
(man)
Binds free
hemoglobin
(Apo)Ferritin Binds free iron
a1-antitrypsin Protease inhibitor
a2-macroglobulin Protease inhibitor
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factor 2-a kinase 2 (PKR/elF2a), Notch, phosphoinosi-
tide 3-kinases (PI-3K), and small GTPases.87–92
TLRs are expressed by a number of different cells,
including dendritic cells, macrophages, B cells, natural
killer (NK) cells, endothelial cells, epithelial cells, and
fibroblasts (Tables 1 and 2); their site of expression
varies, with TLRs 1, 2, 4, 5, 6, and 11 present on the
external plasma membrane and TLRs 3, 7, 8, and 9 in
endosomes.71,93
TLR 2 appears to be of key importance, owing to its
ability to recognize PAMPs as diverse as lipotechoic
acid (from Gram-positive bacteria), peptidoglycan
(from Gram-positive and Gram-negative bacteria),
hemagglutinin (from measles virus), polysaccharides
(from yeasts), lipoproteins (from E. coli, Borrelia
burgdorferi, Mycoplasma spp. and Mycobacterium
tuberculosis), as well as complete pathogens such as
Clostridium spp., Chlamydophila spp., and herpes sim-
plex virus, and a variety of endogenous ligands.94–97
Much of its wide-ranging influence stems from the for-
mation of heterodimers with TLRs 1 and 6.98–100 TLR 4
also has a significant role in triggering the innate
immune response as it recognizes molecules such as LPS
(from Gram-negative bacteria), various viral protein
envelopes, and a large number of endogenous molecules
(Table 2).57,101–103 The vital recognition of LPS by TLR
PAMPs DAMPs 
Pro-inflammatory & anti-inflammatory 
cytokine release via TLRs, NLRs and 
potentially RLRs stimulating NF-κB-mediated 
gene transcription
Primary infectious insult 
Secondary/opportunistic 
infections 
Affected by age, sex, 
genotype, adaptive 
immune memory, 
intercurrent disease states 
Innate immune system 
cell activation (PMNs, 
monocytes, dendritic cells)
Direct host 
cell damage 
Parenchymal cell damage 
(distant)
Adaptive immune 
system activation 
Local vasodilatation 
via nitric oxide release
Acute phase 
response 
proteins 
Endothelial activation – 
enhanced adhesion, transmigration 
and stimulation of tissue factor
(extrinsic) pathway
Hypotension 
Interstitial edema 
Microvascular thromboses 
Reduced organ perfusion, tissue hypoxia, ROS/RNS 
generation, mitochondrial dysfunction, necrosis, 
apoptosis, pyroptosis and autophagy 
Lipopolysaccharide, 
peptidoglycans, lipopeptides, 
muramyl dipeptide, flagellins, 
RNA, DNA 
Heat shock proteins, 
fibronectin, protein 
fragments, HMGB-1 
Immune system cell 
apoptosis/down-regulation 
Fig 1. The pathophysiology of sepsis—an overview. A primary infectious insult—of bacterial, viral, protozoal or fungal origin—dam-
ages host tissues. The ligation of pattern-recognition receptors (TLRs and NLRs) by PAMPs and DAMPs promotes the release of both
pro- and anti-inflammatory cytokines, as well as acute phase proteins, with a number of pathophysiological sequelae that ultimately lead
to organ hypoperfusion, tissue hypoxia, the generation of ROS and RNS, mitochondrial dysfunction and cell death by necrosis, apopto-
sis, pyroptosis, and autophagy. Further DAMPs are generated, helping to perpetuate the inflammatory response, and the death of
immune cells leaves the organism vulnerable to secondary, or opportunistic, infections. Abbreviations: PAMPs = pathogen-associated
molecular patterns; DAMPs = danger-associated molecular patterns; TLRs = Toll-like receptors; NLRs = nucleotide-binding domain,
leucine-rich repeat containing protein; RLR = retinoic acid-inducible gene-1 (RIG-1)-like receptor; NFjB = nuclear factor kappa B;
PMN = polymorphonuclear cell; ROS = reactive oxygen species; RNS = reactive nitrogen species.
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4 appears to be dependent on formation of a complex
with other PRRs, myeloid differentiation protein-2
(MD2), membrane-bound CD14 (mCD14), and lipo-
polysaccharide-binding protein (LBP).71,104 Both TLR 2
and 4 have been extensively researched in human septic
patients, in whom early upregulation of these TLRs can
exacerbate the severity of illness and mortality.19,57
TLR 5 is expressed by epithelial cells of the respira-
tory and intestinal tract and is a PRR for flagellin, an
important component of motile bacteria such as Salmo-
nella spp.105,106 TLR 5 is incriminated in sepsis,107
although exactly how the PAMP and PRR interact
in vivo remains unclear.108 The intracellular TLRs 3, 7,
8, and 9 all share high sequence homology and recog-
nize nucleotides.71,109 TLR 3 is the only TLR yet dis-
covered that does not initiate the MyD88 signaling
pathway, interacting solely with TIR-domain-contain-
ing adaptor molecule 1 (TICAM1, also known as
TRIF) (Fig 2).109,110 TLR 11, to date only identified in
rats and mice, appears to recognize Toxoplasma gondii
and certain pathogens of the urinary tract, although a
role in sepsis has not so far been described.111,112
The Nucleotide-Binding Domain, Leucine-Rich
Repeat Containing Proteins, and Inflammasomes
The realization that TLRs could not account for the
full range of PAMP recognition motivated the discov-
ery of additional intracellular PRRs, including the
NLRs. Of the NLRs, the 2 cytosolic receptors NOD1
and NOD2 were the first to be discovered; subsequent
examination of genomic databases has suggested that
there are at least 23 NLRs in humans and 34 in
mice.113–117 Common to all NLRs is their structure,
comprising a leucine-rich repeat domain (thought to
be the PAMP receptor region), a central NOD
domain, and an N-terminal effector domain responsi-
ble for downstream signaling.118–120 The NLRs are
found in the cytosolic compartment of eukaryotic cells,
although some recent evidence suggests that they can
also be associated with the plasma membrane.121,122
The mechanisms underlying NLR contact with their
respective PAMPs have yet to be confirmed in vivo,123–125
but recognition of the PAMP triggers the activation of
a series of kinases leading to the phosphorylation of
Fig 2. Toll-like receptor (TLR) signaling pathways. The cytoplasmic Toll/interleukin-1 receptor (TIR) domain of the TLRs interacts
with TIR-domain-containing adaptors, such as myeloid differentiation primary response gene 88 (MyD88), TIR-containing adaptor pro-
tein (TIRAP), TIR-domain-containing adaptor molecule 1 (TICAM1, also known as TRIF) and TIR-domain-containing adaptor mole-
cule 2 (TICAM2, also known as TRAM). PAMP binding to the respective receptor results in the activation of either the MyD88 or
TICAM1/TRIF signaling pathways. These pathways involve a series of kinases in the IL-1R associated kinase (IRAK) family, whose
action eventually results in activation of the inhibitor of j B kinase (IKK) enzyme complex and the mitogen-activated protein kinase
(MAPK) pathway. The IKK complex phosphorylates the inhibitory IjBa protein, thus freeing the nuclear transcription factor nuclear
factor kappa B (NF-jB); triggering of the MAPK signaling pathway results in the activation of activator protein 1 (AP-1). Both NF-jB
and AP-1 then initiate the transcription of cytokine genes. Abbreviations: TRAF = TNF receptor-associated factor; RIP = receptor
interacting protein; TAK = TGF-b-activated kinase; NEMO = NF-jB essential modulator; TBK = TRAF family member-associated
NF-jB activator (TANK)-binding kinase; IRF = interferon regulatory factor.
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IjB, mobilization of NF-jB, and activation of MAPK
signaling (Fig 3).126–129 NOD1 (NLR family, caspase
activation, and recruitment domain [CARD] contain-
ing 1; NLRC1) and NOD2 (NLRC2, also known
as CARD15) are known to recognize muropeptides
derived from peptidoglycan, a major structural compo-
nent of both Gram-positive and Gram-negative bacte-
rial cell walls (Table 1).115,118 Whereas the role of
NOD2 is well established in the pathogenesis of
Crohn’s disease,130 little is known about the role of the
NOD proteins in sepsis. However, synthetic NOD1
agonists administered to mice stimulate chemokine
production, neutrophil recruitment,131 and—in one
model—shock and multiple organ dysfunction,132
raising the possibility of NOD1 involvement in the
pathogenesis of sepsis.
A number of studies have been performed on the
role of inflammatory cysteinyl aspartate-specific pro-
teinases, or caspases, in murine and human sepsis.
Caspase-1 has been the focus of particular attention
and is activated by a macromolecular complex of
around 700 kDa—one of a number of inflamma-
somes133—comprising pro-caspase-1 together with
various adapter proteins, including apoptosis-associ-
ated speck-like protein containing a carboxy-terminal
CARD (ASC).133–135 Activation of the currently identi-
fied inflammasomes depends upon the interaction of
NLR family members (NLRC4; NLR family, pyrin
domain containing 1 [NLRP1] and NLRP3) with their
PAMP or DAMP ligands.136–138 Caspase-1 is thought
to be the executioner caspase in inflammation, impor-
tant in the synthesis of active IL-1b and IL-18 and
thus pathogen defense. Hence, mice deficient in cas-
pase-1 are more susceptible to bacterial infections and
sepsis139–141; in contrast, mice deficient in caspase-12,
which normally suppresses caspase-1 activity, show
enhanced bacterial clearance and resistance to sep-
sis.142 Parallel observations have been made in human
patients possessing the full-length caspase-12 pro-
enzyme—uniquely present in approximately 20% of
people of African descent—which attenuates the innate
immune response to endotoxin and is thought to be a
risk factor for the development of severe sepsis.143
Whereas caspase-1 is essential for host defense against
Fig 3. Nucleotide-binding domain, leucine-rich repeat containing protein (NLR) signaling pathways. Upon PAMP ligation, NLRs
recruit the serine-threonine kinase RIP-like interacting caspase-like apoptosis regulatory protein (CLARP) kinase (RICK), also known
as receptor-interacting serine/threonine-protein kinase 2 (RIPK2 or RIP2), which binds to NF-jB essential modulator (NEMO), a sub-
unit of IKK, resulting in the phosphorylation of IjB and the release of NF-jB; RICK also mediates the recruitment of transforming
growth factor b-activated kinase 1 (TAK1) and together these molecules stimulate activation of the mitogen-activated protein kinase
(MAPK) signaling pathway. In common with the TLR family, NLR activation leads to the transcription of inflammatory cytokine genes
via the mobilization of NF-jB and AP-1. Another important consequence of NLR ligation is activation of the inflammasome, a macro-
molecular complex comprising pro-caspase-1 together with various adapter proteins. Caspase-1 is important in the synthesis of active
IL-1b and IL-18, and induces a type of programmed cell death called pyroptosis.
Immunopathology of Sepsis 463
pathogens, its activity needs to be tightly controlled.
Excessive caspase-1 activity and thus endotoxic shock
was induced in mice given high doses of LPS, but mice
deficient in caspase-1,144 or ASC in another study,145
were resistant to the lethal effects of LPS. Inflamma-
some activity has also been linked to the phenomenon
of immunoparalysis. Thus, the expression of mRNA
encoding the key inflammasome components ASC,
NALP1, and caspase-1 was decreased in human mono-
cytes during early septic shock, thought to reflect
monocyte deactivation; furthermore, NALP1 mRNA
abundance was linked to survival in patients with sep-
sis.146 Very little is known about inflammasomes in the
veterinary species, although inflammasome assembly
mRNAs have been analyzed in the ovine jejunum147
and induction of inflammasome genes in the spleen
was documented in septic pigs infected with either
Haemophilus parasuis148 or Streptococcus suis.149
Pattern Recognition Receptors: Veterinary Species
After mapping of the gene sequences for human and
murine PRRs, exploration of the genomic sequence of
other species has allowed the identification of homologs
of the majority of TLRs in dogs,150–154 cats,49,151,155,156
cattle,38,50,51,62,157–168 sheep,48,51,169–173 goats,52,174,175
horses,47,168,176–181 and pigs.169,182–191 Other PRRs have
also been identified in these species, although less is
known about them than the TLRs (Table 3).
Toll-like receptors 1–10 have been identified in the
bovine genome,50,161 with numerous studies document-
ing their expression in tissues as varied as the endo-
metrium,38,163 cornea,158 mammary gland,167,192 skin,51
and lung.168 Whereas most of these studies have uti-
lized PCR techniques to identify TLR expres-
sion,38,51,158,163,167 an increasing number are employing
flow cytometry192,193 or immunohistochemistry.168 TLR
signaling in cattle is similar to that described in mice
and humans (Fig 2)162,192,194 and the PKR/elF2a path-
way appears to be important in bovine viral diarrhea
virus (BVDV) and rotavirus infections.195,196 Compara-
tively little is known about the NLR family in cattle,
although mRNA encoding NOD 1 and 2 has been iden-
tified in bovine mammary tissue.197,198 Because of the
financial implications of Johne’s disease and the cur-
rently unconfirmed link between Mycobacterium avium
ssp. paratuberculosis and Crohn’s disease, a number of
studies have examined the potential role of polymor-
phisms of candidate genes—including TLRs—in sus-
ceptibility to paratuberculosis.199 Recently, TLRs 1–10
have also been cloned and sequenced in sheep48 and
goats.174 Little is currently known about the implication
of TLRs in sepsis of ruminants, although the pathways
involved in triggering SIRS in sheep appear to be simi-
lar to those reported in other species.169,200
The impact of infectious agents upon commercial
viability of pigs and the contribution of this species to
human disease modelling has helped advance the char-
acterization of porcine PRRs.191 Thus, TLRs 1–10
have been cloned and sequenced201–208; surface and
endosomal TLRs have been detected—both by PCR
and immunohistochemistry—in a variety of porcine
tissues and enhanced expression demonstrated in
response to a number of infectious agents and
PAMPs.168,183,209–211 Members of the NLR family
have also been identified212–216 and current research
suggests that porcine PRR signaling pathways are sim-
ilar to those of other mammalian species.169,217
Various members of the TLR family have been iden-
tified in horses, including TLR 2, 3, 4, 5, and 9.47,53
Whereas many of these have been characterized by
PCR,176–179 TLRs 4 and 9 have also been localized by
immunohistochemistry and immunogold electron
microscopy168,179,181—and a recent study demonstrated
TLR 5 expression by equine neutrophils by flow
cytometry.218 Stimulation by PAMPs has increased
gene expression of TLRs 2, 3, and 4 in vitro,177 and
TLR 9 in vivo,181 whereas clinical studies have
reported increased TLR 4 gene expression in both
foals and adult horses with SIRS/sepsis, but no differ-
ences in expression between survivors and nonsurvi-
vors.219,220 Complementary studies have demonstrated
increased plasma endothelin-1 concentrations and
decreased long-term survival in horses with severe
versus mild-to-moderate endotoxemia.221 As for cattle
and pigs, initial investigations have indicated that the
downstream signaling pathways instigated by PAMP
stimulation of equine TLRs 2–4 are similar to those
identified in other species.222 To date, there have been
no published reports on members of the NLR family
in the horse.
Less is currently known about PRRs in small
animals.53–55 Various PCR studies have confirmed the
presence of members of the TLR family in both dogs,
including TLRs 2, 4, 7, and 9,61,151–154,223 and cats,
including TLRs 1–9.49,151,155,156 Comparative examina-
tion of the canine genome has also identified the pres-
ence of genes encoding members of the NLRP family,
integral to inflammasome and thus caspase activa-
tion.224 A number of canine TLRs have also been
detected by immunohistochemical staining and flow
cytometry.168,209,225,226 The use of feline models for
investigation of human diseases as diverse as type 2
diabetes mellitus and human immunodeficiency virus
infection has yielded additional data on PRRs in cats,
including the expression of functional TLRs by the
endocrine pancreas155 and modulation of TLR signal-
ing by retroviral pathogens.156,227 Enhanced expression
of canine TLRs has been observed in clinical cases of
osteoarthritis60 and cystic endometrial hyperplasia/
pyometra61,226; however, the majority of published
research in dogs concerns the expression of PRRs in
the intestinal tract, particularly in relation to inflamma-
tory bowel disease (IBD).150,223,228 Ongoing research is
attempting to identify whether or not certain single
nucleotide polymorphisms (SNPs) of PRRs can be
related to the propensity for particular canine breeds to
develop IBD and other immune-mediated diseases.229–
231 The analysis of SNPs in PRR-encoding genetic
sequences is also an exciting field of research in large
animals,164,213,232 laying the foundation for the breed-
ing of livestock with enhanced disease resistance and
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the design of vaccines better able to target dendritic
cells.191,233 Finally, recent work has documented the
expression of an ortholog of human “triggering recep-
tor expressed on myeloid cells-1” (TREM-1) by canine
neutrophils.234 Expression of TREM-1 was upregulated
by microbial agonists of TLR1/2, TLR2/6, and TLR4/
MD2.234 This receptor, which has shown promise as a
biomarker of sepsis in humans, amplifies pro-inflamma-
tory responses to microbial products.59,235
Inflammatory Mediators: Cytokines and Chemokines
PRR ligation triggers signaling cascades that culmi-
nate in the activation of NF-jB and AP-1 via MyD88
or TICAM1/TRIF (Fig 2).236–238 NF-jB and AP-1
enter the nucleus and activate transcription sites for a
variety of genes, including acute phase proteins, induc-
ible nitric oxide synthase (iNOS), coagulation factors,
and pro-inflammatory cytokines and chemokines, such
as tumor necrosis factor (TNF)-a and ILs-1, 6, 8, and
12. The TICAM1/TRIF pathway results in the phos-
phorylation of interferon regulatory factors 3 and 7
(IRF3, IRF7), which likewise enter the nucleus and
stimulate the transcription of genes encoding interferon
(IFN)a, IFNb, and other type 1 IFN-inducible
genes.236–238
Serum concentrations of TNF-a correlate with death
in certain types of human sepsis.239,240 Studies of
naturally occurring sepsis in veterinary patients have
yielded similar results, although this pattern appears
not to be universal: increased serum concentrations of
TNF-a correlate with mortality in canine parvovirus
and neonatal septicemia in cattle and horses, but not
in septic cats.11,241,242 TNF-a is predominantly pro-
duced by activated macrophages and T cells—but also
by mast cells, B cells, NK cells, neutrophils, endothe-
lial cells, myocytes, osteoblasts, and fibroblasts—as a
26 kDa precursor (pro-TNF) expressed on the plasma
membrane; there it is cleaved by TNF-converting
enzyme (TACE/ADAM17) to yield a 17 kDa soluble
form, both the soluble and membrane-bound forms
appearing to be active.243 TNF-a exerts its effects by
interaction with one of 2 receptors, TNF receptors 1
and 2 (TNFR1, TNFR2).244,245 Activation of TNFR1
appears to mediate the proinflammatory and apoptotic
pathways associated with inflammation, whereas
TNFR2 plays a role in the promotion of tissue repair
and angiogenesis.245 However, the complexity of sig-
naling networks operating in sepsis is underlined by
the observation that NF-jB activity induces molecules
that block apoptosis mediated by TNFR1, suggesting
that integration of the various signals occurs in vivo.246
Some “cooperation” between the 2 receptor types,
particularly at low TNF-a concentrations, is also likely
and stimulation of both TNFRs leads to further
NF-jB and AP-1 release.244,247
Many of the classical features of inflammation can
be attributed to the actions of TNF-a upon the endo-
thelium, with increased production of iNOS and
cyclo-oxygenase 2 (COX-2) leading to vasodilatation
and local slowing of blood flow248; TNF-a also stim-
ulates the expression of endothelial adhesion mole-
cules such as E-selectin, intercellular adhesion
molecule 1 (ICAM-1), and vascular cell adhesion
molecule 1 (VCAM-1).249,250 These 3 molecules lead
to the tethering of leukocytes to the endothelial wall
and their transmigration into the interstitium, accom-
panied by fluid and plasma macromolecules.19 There
is also evidence for the upregulation of TNF-a and
other proinflammatory cytokines in a canine model of
sepsis involving the intravenous infusion of low doses
of LPS: increased serum concentrations of TNF-a,
IL-1b, and IL-6251–253 were accompanied in one of
the studies by increased expression of pulmonary
E-selectin and ICAM-1 and the influx of neutroph-
ils—although whether the LPS induced the expression
of the adhesion molecules directly or via induction of
the proinflammatory cytokines, or both, remained
unclear.251 A similar phenomenon of up-regulation of
proinflammatory cytokines, including TNF-a, has also
been observed in cats254 and horses255–257 treated with
intravenous LPS, as well as the transcription of neu-
trophil chemoattractants by equine endothelial cells
stimulated by Th2 cytokines.258 Furthermore, concen-
trations of TNF-a, IL-6, and endotoxin were all
higher in the blood and peritoneal fluid of horses
with colic than in a healthy control group.259 The
stimulation of feline whole blood with various
PAMPs has also elicited the synthesis of pro-
inflammatory cytokines, including TNF, IL-1b, and
CXCL-8.260 Plasma nitrite and nitrate, oxidation
products of NO, have been examined in canine sepsis,
in which they were present at higher concentrations
than in dogs with SIRS alone.261 An additional study
showed that the inflammatory response to the intrave-
nous administration of LPS, examined by measuring
serum concentrations of TNF-a, IL-1 and IL-6, was
mitigated in dogs fed a diet rich in fish oils, suggest-
ing that diet may be an adjunct to conventional anti-
inflammatory treatment.262 In addition to the upregu-
lation of iNOS, COX-2, and adhesion molecules,
TNF-a also induces the expression of procoagulant
proteins such as tissue factor (TF)—and down-regu-
lates anti-coagulant factors such as thrombomodu-
lin—leading to activation of the coagulation
cascade.263 Despite the important role for TNF-a in
endothelial activation, experimental evidence suggests
that direct stimulation of TLRs expressed by endothe-
lial and vascular smooth muscle cells may provide an
alternative pathway for the vascular dysfunction seen
in sepsis.264–266
In addition to TNF-a, NF-jB activation results in
the transcription of a number of proinflammatory
interleukins, such as IL-1, IL-6, CXCL-8 (IL-8), and
IL-12 (Fig 1). IL-1 acts in a synergistic manner with
TNF-a in the “hyperacute” period after innate
immune stimulation in sepsis.267,268 Two proinflamma-
tory forms of IL-1 (IL-1a and IL-1b) have been identi-
fied and induce the synthesis of adhesion molecules
and cytokines by endothelial cells, encouraging leuko-
cyte activation, endothelial tethering, and transmigra-
tion into the interstitium.269,270 IL-1 also upregulates
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iNOS and COX2 production, acts as the major endog-
enous pyrogen in fever, and increases corticosteroid
release via hypothalamic effects.269,271
Another important proinflammatory cytokine in sep-
sis is IL-6: as well as stimulatory effects upon leuko-
cyte activation and myeloid progenitor cell
proliferation, IL-6 also triggers the acute phase
response and is a powerful pyrogen.272,273 Like TNF-a
and IL-1, plasma concentrations of IL-6 are increased
in sepsis and may be predictive of progression to mul-
tiple organ dysfunction and death.17,274,275 Whereas
enhanced gene expression of IL-6 correlates with death
in septic foals, the opposite relationship appears to
hold for serum IL-6 concentrations.219,276 However,
increased serum concentrations of IL-6 and IL-1b do
correlate with death in reports of naturally occurring
sepsis in dogs and cats.11,13
Serum concentrations of anti-inflammatory cytokines,
most notably IL-10, also increase in sepsis.277,278 This
acts not only to inhibit the release of TNF-a, IL-1b, and
IL-6 from monocytes and macrophages, but also to
induce the production of IL-1 receptor antagonist pro-
tein (IRAP-1) and soluble TNFR, thus reducing circu-
lating concentrations of these cytokines.279 The critical
role of IL-10 in mediating the balance between pro- and
anti-inflammatory processes can be seen in experimental
models: IL-10 knockout mice are profoundly susceptible
to sepsis, whereas IL-10 administration prevents these
consequences.280 In clinical situations, however, the pat-
tern appears to be more complex, with increased serum
IL-10 concentrations associated with mortality in septic
foals and humans,281,282 but a lower prevalence of feline
infectious peritonitis in cats infected with feline
coronavirus.283
Two additional cytokines have recently been iden-
tified as being critical in sepsis. Macrophage migra-
tory inhibitory factor (MIF), produced by the
anterior pituitary gland, is present at increased con-
centrations in SIRS and sepsis284,285; serum concen-
trations have not only correlated with mortality, but
inhibition of MIF appears to be protective.286–288
Although the trigger for MIF release in vivo is
unclear, it is thought to delay apoptosis of activated
monocytes and macrophages, thus helping to perpet-
uate a proinflammatory state.288 High mobility group
box protein 1 (HMGB-1) is an endogenous protein
involved in nuclear DNA stabilization.289 However,
after necrotic or apoptotic cell death, it is released
into the circulation where it has direct pro-inflamma-
tory actions.290 In addition, HMGB-1 appears to
potentiate the effect of certain PAMPs and DAMPs
upon TLR-2, TLR-4, and the receptor for advanced
glycation end products (RAGE).291 HMGB-1 was
initially reported as a late inflammatory mediator in
sepsis,292 although ongoing research has highlighted
a number of roles in tissue repair and angiogene-
sis.293 Circulating concentrations of HMGB-1 appear
to correlate with mortality in canine SIRS
patients,294 but were unable to predict hospital mor-
tality in 1 study of septic human patients.295
The Acute Phase Response
In addition to the release of cytokines and chemo-
kines from activated immune cells, triggering of PRRs
also bring about the release of large quantities of acute
phase proteins (APPs) from hepatocytes; these proteins
have a variety of functions designed to re-establish
homeostasis, assisting in pathogen elimination and
subduing inflammation.296,297 The acute phase
response is characterized by fever, neutrophilia, activa-
tion of the coagulation, and complement cascades
(classical, alternative, and mannose-binding lectin
pathways), serum iron and zinc binding, enhanced glu-
coneogenesis, increased muscle catabolism, and altered
lipid metabolism.297–299
In general, 2 groups of APPs are recognized: type
I, induced by IL-1a, IL-1b, and TNF-a, and type II,
induced by IL-6.298 As a consequence of the up-regu-
lation of APP production, concentrations of other
plasma proteins such as albumin, protein C, protein
S, and antithrombin (collectively known as negative
APPs) decrease.299,300 Granulocyte colony-stimulating
factor (G-CSF) released from monocytes is also an
important component of the acute phase response,
thought to mediate a protective role against bacterial
infection by virtue of its impact on neutrophils.301 A
number of APPs have been characterized in veteri-
nary species, including dogs, cats, cattle, sheep,
horses, and chicken,297,302 and they have been used as
biomarkers of inflammation in both research and
clinical arenas in these species.303,304 Recent studies
have identified adiponectin and insulin-like growth
factor-1 as negative acute phase proteins in a canine
model of endotoxemia.305
Much research has been conducted to determine
whether or not serum levels of APPs are predictive
of survival in sepsis, with procalcitonin and C-reac-
tive protein (CRP) the focus of particular atten-
tion.306 Plasma procalcitonin concentrations appear
to correlate with bacteremia and organ dysfunction
in human clinical studies.306,307 Whereas it also
appears to be a canine APP, it does not allow the
discrimination of inflammatory or infectious from
neoplastic disease when measured as a whole blood
PCR assay308; however, extrathyroidal procalcitonin
gene expression was documented in dogs with SIRS
but not in healthy animals in a preliminary observa-
tional study.309 The utility of CRP measurements
has been assessed in a number of studies examining
infectious,310,311 inflammatory,312–319 neoplastic,320,321
and endocrine322 diseases in the dog, including criti-
cally ill dogs323: in general, serum CRP concentra-
tions provide a sensitive but nonspecific means of
measuring inflammation, offering diagnostic and
prognostic information in some disorders but not
others. A recent study of SIRS and sepsis in dogs
demonstrated a correlation between decreasing serum
CRP concentration and recovery from disease, sug-
gesting its use as a prognostic biomarker in this con-
text.324
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The Interaction of Inflammation and Coagulation in
Sepsis
Despite not classically considered part of the innate
immune response, the prevalence of coagulation disor-
ders and disseminated intravascular coagulation (DIC)
in sepsis underlines the intimate link between the
inflammatory and coagulation pathways.325,326 On a
local scale, activation of coagulation may act defen-
sively to impede the dispersal of pathogens and inflam-
matory mediators from the site of insult.327 Clinical
studies have supported experimental models demon-
strating increased activation of coagulation, as well as
downregulation of anticoagulant mechanisms and
reduced fibrinolysis, in human SIRS and sepsis
patients.266,328 Similar findings have also been reported
in dogs329 and horses.330 Whereas DIC331 and pulmo-
nary thromboembolism332 have both been recorded in
association with sepsis in cats, experimental models of
endotoxin infusion in this species have yielded variable
results,333,334 a recent study failing to elicit any biologi-
cally significant alterations in coagulation parame-
ters,334 underlining the multifactorial pathogenesis of
coagulopathies in clinical patients.
A detailed description of the complexities of the
interaction between inflammation and coagulation is
beyond the scope of this article; however, several com-
prehensive reviews of hemostasis in SIRS and sepsis in
veterinary species have recently been published and an
overview of key interactions is presented in Fig 4335–337
In brief, key to the triggering of the coagulation path-
way in sepsis is tissue factor (TF), which initiates coag-
ulation via the contact activation (extrinsic) pathway.
In health, lack of TF exposure within the vascular sys-
tem and the presence of various circulating proteins—
such as protein C, antithrombin, and tissue factor
plasminogen inhibitor—modulate coagulation by the
prevention of TF activation.266,335 The expression of
TF by monocytes or macrophages and tissue
parenchymal cells is activated by various inflammatory
cytokines, CRP, and PAMPs such as LPS335,338—a
phenomenon that has also been documented in cats339
and horses (earlier studies in this species citing “proco-
agulant activity” rather than TF per se).340–342
Although findings differ between species, large num-
bers of TF-expressing microparticles have been identi-
fied in blood samples from septic human patients and
may correlate with mortality.343,344 These microparti-
cles are released from a variety of activated or apopto-
tic cells—such as platelets, monocytes, erythrocytes,
and endothelial cells—and their interaction with endo-
thelial cells and platelets drives the coagulation path-
way.345–347 Although only an indirect measure, plasma
von Willebrand factor concentrations were higher in
septic dogs than those in healthy control animals, sug-
gesting that endothelial cell activation also occurs in
canine sepsis.348 Interestingly, platelets enhanced endo-
toxin-induced equine monocyte TF activity in vitro341—
although whether microparticles derived from platelets
or other sources play a role in the pathogenesis of
equine sepsis in vivo remains unknown. Additional
work in an equine model of endotoxemia has shown
that large volume resuscitation has no impact on coag-
ulation parameters beyond the changes attributed to
endotoxemia, providing useful additional data to
inform the treatment of sepsis in this species.349
Whereas much research has been directed toward
the inhibition of coagulation in sepsis, only activated
protein C has shown any benefit in human clinical tri-
als.350,351 The antithrombotic and anti-inflammatory
properties of recombinant human activated protein C
led to recommendations for its use in severe sepsis in
2004352 and 2008,353 but a recent meta-analysis found
no evidence in support of its administration in the
treatment of severe sepsis or septic shock.354 Indeed,
there is still debate about its mechanism of action
and, as yet, little experience of its use in veterinary
medicine, despite encouraging pharmacological data in
experimental models.266,355,356
In addition to the role of TF in initiating coagula-
tion in the presence of inflammation, activated plate-
lets and endothelial cells—as well as bacterial
surfaces—also trigger the contact phase system, lead-
ing to the formation of kallikrein and bradyki-
nin.357,358 Bradykinin in turn enhances vasodilatation
and increases vascular permeability, as well as reducing
platelet function359; kallikrein accelerates fibrinolysis
by conversion of plasminogen to plasmin and causes
additional activation of Factor XII, leading to stimula-
tion of the classical complement pathway.360,361
A final connection between coagulation and inflam-
mation in sepsis has become apparent with the recent
exploration of the role of “a disintegrin-like and metal-
loproteinase with thrombospondin type-I motifs-13”
(ADAMTS-13). ADAMTS-13 is produced by the stel-
late (Ito) cells of the liver and acts to cleave ultra-large
von Willebrand’s Factor (vWF) multimers into smaller
multimers.362 These ultra-large vWF multimers are
released from endothelial stores after inflammation
and lead to platelet activation and aggregation; the
ensuing microthrombi further compromise tissue blood
flow, leading to additional propagation of the pro-
inflammatory state.363 Although not yet identified in
clinical veterinary species, decreased plasma ADAM-
TS-13 activity is associated with a poor prognosis in
human sepsis patients364–366; decreased activity is
attributed to both a diminution of hepatic production
and an increase in breakdown by plasma proteases.366
The Compensatory Anti-Inflammatory Response
Syndrome and Cell Death
Ongoing investigation of the molecular mechanisms
of the SIRS response, as well as the notable failure of
therapeutic blockade of proinflammatory mediators, led
to the realization that the mortality associated with sep-
sis could not be explained solely by an uncontrollable
“cytokine storm”.367,368 This resulted in the concept of
an opposing “compensatory anti-inflammatory response
syndrome” (CARS), thought to be an adaptive response
to the excessive proinflammatory process in SIRS and
sepsis.367,369 Whereas an appropriate balance is struck
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in the vast majority of instances of host-defense chal-
lenge, this is lost in sepsis—leading either to an uncon-
trolled proinflammatory reaction to infection, resulting
in organ dysfunction, an undesirable compromise of the
immune system permitting opportunistic infection (the
“second hit”), or a combination of both.367
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Fig 4. Points of interaction of the coagulation cascade and sepsis. In the absence of inflammation, various anticoagulant mechanisms
exist to prevent activation of coagulation. Thrombomodulin and endothelial protein C receptor interact with thrombin to activate protein
C (aPC), which in turn interacts with protein S to inactivate factor V. Endothelial cells also express tissue factor pathway inhibitor (TFPI)
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activation and adhesion. After triggering of the contact activation (TF) pathway, the interaction of microparticles with endothelial cells
and platelets further drives the coagulation pathway. The presence of coagulation pathway components (TF-VIIa complex, Xa, Va,
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process by stimulating the further release of mediators (TNFa, IL-6 and CXCL-8), platelet activation and cell death. Triggering of the
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Rather than a sequential or compensatory change,
as was initially proposed, SIRS and CARS appear to
occur simultaneously, and act to balance the host’s
need to maintain defense while minimizing self-induced
tissue damage.370 Serum concentrations of both pro-
and anti-inflammatory mediators increase early on in
sepsis370; likewise, concentrations of a variety of both
types of mediators (eg, IL-6, IRAP-1) are predictive of
septic morbidity or mortality.370–372 Thus the changes
in cytokine profile are both dynamic and
heterogeneous, indicating that prescriptive immuno-
modulatory therapies are unlikely to meet with
success.370,373 Furthermore, apoptosis of lymphocytes,
hepatocytes, gastrointestinal epithelial cells and endo-
thelial cells is increased, whereas that of neutrophils is
decreased.374,375 Neutrophil function is also altered:
both the migration of neutrophils to infected tis-
sues376,377 and their antimicrobial function378 is dimin-
ished; moreover, peritoneal neutrophils are a potential
source of IL-10, suppressing inflammatory monocytes
in a model of polymicrobial sepsis.379 Although mono-
cyte survival appears unaltered, sepsis results in the
production of molecules such as IL-1 receptor associ-
ated kinase M (IRAK-M), MyD88 short variant
(MyD88s), and A20-binding inhibitor of NF-jB
activation3 (ABIN-3), which reduce activation of the
NF-jB signaling pathway and therefore dampen the
response to PAMP recognition.380,381 Monocyte func-
tion is impaired in sepsis, with decreased expression of
the MHC class II molecule human leukocyte antigen–
DR (HLA-DR)382,383 and decreased inflammasome
expression.146 Longitudinal observational studies in
human patients indicate that a failure to regain >70%
normal monocytic expression of HLA-DR is associ-
ated with an increased risk of secondary bacterial
infection and decreased survival.384 In addition to
these changes in antigen-presenting function of mono-
cytes, dendritic cells also undergo increased apoptosis
in sepsis, further impairing the host’s ability to
respond to pathogens.385
Although apoptosis, or type 1 programmed cell
death (PCD), is responsible for the majority of
immune cell death in sepsis and is implicated in
immunoparalysis, alternative pathways also play a
role.386,387 Autophagy is a cellular mechanism that
primarily acts as a cytoplasmic “clean-up” process, as
well as assisting in delivery of proteins to antigen pre-
sentation pathways; however, it may also mediate type
II PCD and interact with apoptosis.388,389 Much cur-
rent interest has been directed toward the role of auto-
phagy in trauma and sepsis, although whether it acts
in a cytoprotective role or as a mechanism of PCD, or
both, remains unclear.386,390 A final mechanism of
interest in the pathogenesis of sepsis is pyroptosis, a
term used to describe the process of caspase-1-medi-
ated PCD, which is distinct from death mediated by
the apoptotic caspases 3, 6, and 8.391 Although some
question whether pyroptosis is truly a unique cell
death mechanism, or simply a special case of apoptosis
or necrosis (oncosis),392 it is characterized by rapid
plasma membrane rupture and release of proinflamma-
tory intracellular contents, some of which may act as
DAMPs.393 One of the targets of caspase-1 during sep-
sis is the glycolytic pathway.394
A number of studies also suggest an important role
for apoptosis in the pathogenesis of SIRS, sepsis, and
infectious disease in veterinary species. Apoptotic cells
were observed in the liver, kidney, thymus, stomach,
and lymphocyte population of endotoxemic piglets395
and the primary and secondary lymphoid organs of pigs
infected with classical swine fever virus.396 LPS and
TNF-a both induced apoptosis of bovine glomerular
endothelial cells, modeling a potential pathomechanism
of acute renal failure in Gram-negative sepsis397; this
phenomenon could be potently inhibited by glucocor-
ticoids in vitro.398 Haemophilus somnus, a Gram-nega-
tive pathogen of cattle that causes sepsis and vasculitis,
induces caspases 3 and 8, and subsequent apoptosis, of
endothelial cells in vitro399; furthermore, the bacterium
stimulates platelets that are in turn able to induce endo-
thelial cell apoptosis by a contact-dependent mecha-
nism involving the activation of caspases 8 and 9 and
the synthesis of reactive oxygen species.400 The activity
of matrix metalloproteinases 2 and 9 and the expression
of phosphorylated Paxillin showed positive correlation
with cardiomyocyte apoptosis in an ovine model of
endotoxemic shock,401 whereas apoptosis of peripheral
blood mononuclear cells and splenocytes of sheep
infected with bluetongue virus was thought to contrib-
ute to immunosuppression in this disease.402 Ileal epi-
thelial apoptosis was documented in one feline model
of endotoxemia,403 although a second demonstrated
lymphocyte apoptosis in the spleen and Peyer’s
patches.334 Apoptosis of T cells also contributes to the
immunosuppression characteristic of feline immunodefi-
ciency virus infection.404 Finally, apoptosis of intestinal
epithelial cells was observed in a canine model of sepsis
induced by the intravenous infusion of E. coli.405
Regulatory T Cells and Sepsis
One of the key features of the adaptive immune sys-
tem is its ability to generate antigen-specific receptors
with an enormous diversity of specificities, some of
which may recognize host-derived epitopes.406,407 The
majority of potentially autoaggressive thymocytes are
deleted in the thymic medulla in a process called nega-
tive selection.408,409 However, this process of central
tolerance is imperfect and underlines the importance of
a number of peripheral tolerance mechanisms, includ-
ing clonal deletion, functional inactivation (anergy),
and phenotypic skewing.410–412 Although a subject of
debate for many years, a population of Tregs is now
known to play a major role in peripheral tolerance,
complementing the preceding (intrinsic) mecha-
nisms.413–415 Little is currently known about tolerance
mechanisms in veterinary species,416 but Tregs have
been identified in cats,417–423 dogs,424–433 pigs,434–442
cows,443–446 sheep,447,448 and horses.449–454
Both naturally occurring and peripherally induced
Tregs have been characterized—the former the product
of a pathway of thymic differentiation called altered
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negative selection and the latter the product of periph-
eral activation of conventional T cells in the context of
an environment rich in transforming growth factor b
(TGF-b) or IL-10.455–457 Naturally occurring Tregs
have been identified by their constitutive expression of
the IL-2 receptor a chain (CD25) and Forkhead box
P3 (FOXP3), a transcription factor that plays a pivotal
role in both their ontogeny and peripheral function.
FOXP3 acts to stabilize the Treg transcriptome by
repressing a number of pro-inflammatory and growth-
promoting genes—for example, IL-2 and IFNG—while
activating others encoding key molecules involved in
Treg function—for example, CTLA4 and CD25.458,459
Naturally occurring Tregs are known to interact with
cells of both the innate and adaptive immune sys-
tems—including monocytes, macrophages, natural
killer cells, neutrophils, mast cells, dendritic cells, and
both T and B cells—generally mediating a suppressive
function to prevent the development of autoaggressive
responses and maintain the population of peripheral
CD4+ T cells, thus contributing to immune system
homeostasis.456,460,461 Tregs are also known to express
a variety of TLRs, stimulation of which has aug-
mented or abolished regulatory function in various
studies.462–465 The molecular mechanisms of immune
suppression mediated by naturally occurring Tregs
have not been fully elucidated, but involve cell contact-
dependent interactions, induction of cell death, and
secretion of immunosuppressive cytokines, including
IL-10 and TGF-b.416,456
Various studies have documented increased propor-
tions of Tregs in human sepsis during the phase of
immunoparalysis,466–469 but the role of this change
remains unclear because depletion of Tregs in murine
models of sepsis has yielded variable conclusions
between models, either improving, enhancing, or bear-
ing no influence on mortality.470–472 Given the ability of
Tregs to induce the alternative activation pathway of
macrophages473 and to inhibit the LPS-induced survival
of monocytes through a proapoptotic mechanism
involving the Fas/FasL pathway,474 they may make a
potentially significant contribution to immune system
dysfunction in human septic patients,468,469,475,476
although this is still a controversial area.477
Additional research is required to elucidate the role of
Tregs in sepsis, as well as to identify their mechanisms
of action in this context. Moreover, to the authors’
knowledge no veterinary studies have interrogated Treg
number or function in septic patients to date. Pharma-
cological manipulation of Treg activity continues to be
explored experimentally and may eventually translate to
clinical cases; however, therapeutic interventions to alter
the resistance of immune cells to Treg suppression may
prove an equally valid alternative approach.478,479
Conclusions
As is apparent from Figure 1, a broad concept of
the immunopathological mechanisms underlying sepsis
is now generally accepted. However, many of the
molecular details are both complex and incompletely
elucidated. Ongoing research has also indicated the
existence of multiple redundant pathways within the
innate immune response, potentially explaining the
failure of many highly selective therapeutic interven-
tions.14,19
A single “magic bullet” for the treatment of sepsis is
highly unlikely to exist: an individually tailored set of
therapies, based on point-of-care assessment of the
immunopathological status of the patient, is the likely
future—albeit a distant one.373 Various human studies
have resulted in the publication of consensus state-
ments regarding the treatment of sepsis,352,353 but cur-
rent veterinary evidence to substantiate these
interventions is thin on the ground. What has become
evident is that outside the experimental laboratory, the
heterogeneous nature of the septic patient population
means that clinical trials must be carefully designed to
obtain meaningful data.480–482 Ongoing basic research
into the immunopathology of sepsis in clinical veteri-
nary species is equally important, to elucidate the
underlying molecular mechanisms and thus direct clini-
cal studies to those aspects of disease likely to benefit
the greatest number of patients.
Acknowledgments
The authors acknowledge funding from the Biotech-
nology and Biological Sciences Research Council,
Novartis Animal Health, the European College of Vet-
erinary Internal Medicine, and the American College
of Veterinary Emergency and Critical Care for work
on canine regulatory T cells and sepsis.
References
1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis
and organ failure and guidelines for the use of innovative thera-
pies in sepsis. The ACCP/SCCM Consensus Conference Commit-
tee. American College of Chest Physicians/Society of Critical
Care Medicine. Chest 1992;101:1644–1655.
2. Hotchkiss RS, Karl IE. The pathophysiology and treatment
of sepsis. N Engl J Med 2003;348:138–150.
3. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/
ESICM/ACCP/ATS/SIS International Sepsis Definitions Confer-
ence. Crit Care Med 2003;31:1250–1256.
4. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/
ESICM/ACCP/ATS/SIS International Sepsis Definitions Confer-
ence. Intensive Care Med 2003;29:530–538.
5. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European
intensive care units: Results of the SOAP study. Crit Care Med
2006;34:344–353.
6. Bone RC. The sepsis syndrome. Definition and general
approach to management. Clin Chest Med 1996;17:175–181.
7. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemi-
ology of severe sepsis in the United States: Analysis of incidence,
outcome, and associated costs of care. Crit Care Med
2001;29:1303–1310.
8. Martin GS, Mannino DM, Eaton S, et al. The epidemiol-
ogy of sepsis in the United States from 1979 through 2000. N
Engl J Med 2003;348:1546–1554.
9. Brady CA, Otto CM. Systemic inflammatory response syn-
drome, sepsis, and multiple organ dysfunction. Vet Clin North
Am Small Anim Pract 2001;31:1147–1162, v-vi.
470 Lewis et al
10. Hoffman AM, Staempfli HR, Willan A. Prognostic vari-
ables for survival of neonatal foals under intensive care. J Vet
Intern Med 1992;6:89–95.
11. Declue AE, Delgado C, Chang CH, et al. Clinical and
immunologic assessment of sepsis and the systemic inflammatory
response syndrome in cats. J Am VetMed Assoc 2011;238:890–897.
12. Hurcombe SD, Toribio RE, Slovis NM, et al. Calcium
regulating hormones and serum calcium and magnesium concen-
trations in septic and critically ill foals and their association with
survival. J Vet Intern Med 2009;23:335–343.
13. Rau S, Kohn B, Richter C, et al. Plasma interleukin-6
response is predictive for severity and mortality in canine sys-
temic inflammatory response syndrome and sepsis. Vet Clin
Pathol 2007;36:253–260.
14. Chong DL, Sriskandan S. Pro-inflammatory mechanisms
in sepsis. Contrib Microbiol 2011;17:86–107.
15. Cinel I, Opal SM. Molecular biology of inflammation and
sepsis: A primer. Crit Care Med 2009;37:291–304.
16. Cohen J. The immunopathogenesis of sepsis. Nature
2002;420:885–891.
17. Ivady B, Beres BJ, Szabo D. Recent advances in sepsis
research: Novel biomarkers and therapeutic targets. Curr Med
Chem 2011;18:3211–3225.
18. Remick DG. Pathophysiology of sepsis. Am J Pathol
2007;170:1435–1444.
19. Sriskandan S, Altmann DM. The immunology of sepsis.
J Pathol 2008;214:211–223.
20. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C,
et al. The pathogenesis of sepsis. Annu Rev Pathol 2011;6:19–48.
21. Ganz T, Weiss J. Antimicrobial peptides of phagocytes
and epithelia. Semin Hematol 1997;34:343–354.
22. Hoffmann JA, Kafatos FC, Janeway CA, et al. Phyloge-
netic perspectives in innate immunity. Science 1999;284:1313–1318.
23. Zasloff M. Antimicrobial peptides in health and disease. N
Engl J Med 2002;347:1199–1200.
24. Brogden KA, Ackermann M, McCray PB Jr, et al. Anti-
microbial peptides in animals and their role in host defences. Int
J Antimicrob Agents 2003;22:465–478.
25. Linde A, Ross CR, Davis EG, et al. Innate immunity and
host defense peptides in veterinary medicine. J Vet Intern Med
2008;22:247–265.
26. Shai Y. Mechanism of the binding, insertion and destabili-
zation of phospholipid bilayer membranes by alpha-helical anti-
microbial and cell non-selective membrane-lytic peptides.
Biochim Biophys Acta 1999;1462:55–70.
27. Wilmes M, Cammue BP, Sahl HG, et al. Antibiotic activi-
ties of host defense peptides: More to it than lipid bilayer pertur-
bation. Nat Prod Rep 2011;28:1350–1358.
28. Ali AS, Townes CL, Hall J, et al. Maintaining a sterile
urinary tract: The role of antimicrobial peptides. J Urol
2009;182:21–28.
29. Diamond G, Beckloff N, Ryan LK. Host defense peptides
in the oral cavity and the lung: Similarities and differences.
J Dent Res 2008;87:915–927.
30. Ham M, Kaunitz JD. Gastroduodenal mucosal defense.
Curr Opin Gastroenterol 2008;24:665–673.
31. Laube DM, Yim S, Ryan LK, et al. Antimicrobial pep-
tides in the airway. Curr Top Microbiol Immunol 2006;306:153–
182.
32. Huttner KM, Brezinski-Caliguri DJ, Mahoney MM, et al.
Antimicrobial peptide expression is developmentally regulated in
the ovine gastrointestinal tract. J Nutr 1998;128:297S–299S.
33. Sang Y, Ortega MT, Blecha F, et al. Molecular cloning
and characterization of three beta-defensins from canine testes.
Infect Immun 2005;73:2611–2620.
34. Salaun B, de Saint-Vis B, Pacheco N, et al. CD208/den-
dritic cell-lysosomal associated membrane protein is a marker of
normal and transformed type II pneumocytes. Am J Pathol
2004;164:861–871.
35. Matzinger P. Friendly and dangerous signals: Is the tissue
in control? Nat Immunol 2007;8:11–13.
36. Frantz S, Ertl G, Bauersachs J. Toll-like receptor signaling
in the ischemic heart. Front Biosci 2008;13:5772–5779.
37. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al.
Recognition of commensal microflora by toll-like receptors is
required for intestinal homeostasis. Cell 2004;118:229–241.
38. Davies D, Meade KG, Herath S, et al. Toll-like receptor
and antimicrobial peptide expression in the bovine endometrium.
Reprod Biol Endocrinol 2008;6:53.
39. Bianchi ME. DAMPs, PAMPs and alarmins: All we need
to know about danger. J Leukoc Biol 2007;81:1–5.
40. Gallucci S, Matzinger P. Danger signals: SOS to the
immune system. Curr Opin Immunol 2001;13:114–119.
41. Matzinger P. Tolerance, danger, and the extended family.
Annu Rev Immunol 1994;12:991–1045.
42. Akira S, Uematsu S, Takeuchi O. Pathogen recognition
and innate immunity. Cell 2006;124:783–801.
43. Miyake K. Innate immune sensing of pathogens and dan-
ger signals by cell surface Toll-like receptors. Semin Immunol
2007;19:3–10.
44. Chen GY, Tang J, Zheng P, et al. CD24 and Siglec-10
selectively repress tissue damage-induced immune responses. Sci-
ence 2009;323:1722–1725.
45. Chun KH, Seong SY. CD14 but not MD2 transmit sig-
nals from DAMP. Int Immunopharmacol 2010;10:98–106.
46. Mollen KP, Anand RJ, Tsung A, et al. Emerging para-
digm: Toll-like receptor 4-sentinel for the detection of tissue dam-
age. Shock 2006;26:430–437.
47. Astakhova NM, Perelygin AA, Zharkikh AA, et al. Char-
acterization of equine and other vertebrate TLR3, TLR7, and
TLR8 genes. Immunogenetics 2009;61:529–539.
48. Chang JS, Russell GC, Jann O, et al. Molecular cloning
and characterization of Toll-like receptors 1-10 in sheep. Vet
Immunol Immunopathol 2009;127:94–105.
49. Ignacio G, Nordone S, Howard KE, et al. Toll-like recep-
tor expression in feline lymphoid tissues. Vet Immunol Immuno-
pathol 2005;106:229–237.
50. McGuire K, Jones M, Werling D, et al. Radiation hybrid
mapping of all 10 characterized bovine Toll-like receptors. Anim
Genet 2006;37:47–50.
51. Menzies M, Ingham A. Identification and expression of
Toll-like receptors 1-10 in selected bovine and ovine tissues. Vet
Immunol Immunopathol 2006;109:23–30.
52. Tirumurugaan KG, Dhanasekaran S, Raj GD, et al. Dif-
ferential expression of toll-like receptor mRNA in selected tissues
of goat (Capra hircus). Vet Immunol Immunopathol
2010;133:296–301.
53. Turin L, Riva F. Toll-like receptor family in domestic ani-
mal species. Crit Rev Immunol 2008;28:513–538.
54. Werling D, Coffey TJ. Pattern recognition receptors in
companion and farm animals The key to unlocking the door to
animal disease? Vet J 2007;174:240–251.
55. Werling D, Jann OC, Offord V, et al. Variation matters:
TLR structure and species-specific pathogen recognition. Trends
Immunol 2009;30:124–130.
56. Williams DL, Ha T, Li C, et al. Modulation of tissue
Toll-like receptor 2 and 4 during the early phases of polymicrobi-
al sepsis correlates with mortality. Crit Care Med 2003;31:1808–
1818.
57. Tsujimoto H, Ono S, Efron PA, et al. Role of Toll-like
receptors in the development of sepsis. Shock 2008;29:315–321.
58. Sato S, Nomura F, Kawai T, et al. Synergy and cross-tol-
erance between Toll-like receptor (TLR) 2- and TLR4-mediated
signaling pathways. J Immunol 2000;165:7096–7101.
Immunopathology of Sepsis 471
59. Ford JW, McVicar DW. TREM and TREM-like receptors
in inflammation and disease. Curr Opin Immunol 2009;21:38–46.
60. Kuroki K, Stoker AM, Sims HJ, et al. Expression of Toll-
like receptors 2 and 4 in stifle joint synovial tissues of dogs with
or without osteoarthritis. Am J Vet Res 2010;71:750–754.
61. Silva E, Leitao S, Henriques S, et al. Gene transcription of
TLR2, TLR4, LPS ligands and prostaglandin synthesis enzymes
are up-regulated in canine uteri with cystic endometrial hyperpla-
sia-pyometra complex. J Reprod Immunol 2010;84:66–74.
62. Taraktsoglou M, Szalabska U, Magee DA, et al. Tran-
scriptional profiling of immune genes in bovine monocyte-derived
macrophages exposed to bacterial antigens. Vet Immunol Immu-
nopathol 2011;140:130–139.
63. Gundersen Y, Vaagenes P, Thrane I, et al. Early time
course of altered leukocyte response to lipopolysaccharide and
peptidoglycan in porcine gunshot injury. Acta Anaesthesiol
Scand 2008;52:1231–1237.
64. Deitschel SJ, Kerl ME, Chang CH, et al. Age-associated
changes to pathogen-associated molecular pattern-induced
inflammatory mediator production in dogs. J Vet Emerg Crit
Care (San Antonio) 2010;20:494–502.
65. Benbarek H, Deby-Dupont G, Caudron I, et al. Interac-
tions between lipopolysaccharides and blood factors on the stim-
ulation of equine polymorphonuclear neutrophils. Vet Immunol
Immunopathol 1998;64:313–322.
66. Declue AE, Johnson PJ, Day JL, et al. Pathogen associ-
ated molecular pattern motifs from Gram-positive and Gram-
negative bacteria induce different inflammatory mediator profiles
in equine blood. Vet J 2011;00:00–00.
67. Fowler BL, Axiak SM, Declue AE. Blunted pathogen-
associated molecular pattern motif induced TNF, IL-6 and IL-10
production from whole blood in dogs with lymphoma. Vet
Immunol Immunopathol 2011;144:167–171.
68. Ishii KJ, Koyama S, Nakagawa A, et al. Host innate
immune receptors and beyond: Making sense of microbial infec-
tions. Cell Host Microbe 2008;3:352–363.
69. Medzhitov R, Janeway C, Jr. Innate immune recognition:
Mechanisms and pathways. Immunol Rev 2000;173:89–97.
70. Zak DE, Aderem A. Systems biology of innate immunity.
Immunol Rev 2009;227:264–282.
71. Kawai T, Akira S. Toll-like receptors and their crosstalk
with other innate receptors in infection and immunity. Immunity
2011;34:637–650.
72. Koyama S, Ishii KJ, Kumar H, et al. Differential role of
TLR- and RLR-signaling in the immune responses to influenza A
virus infection and vaccination. J Immunol 2007;179:4711–4720.
73. Takahashi K, Kawai T, Kumar H, et al. Roles of caspase-
8 and caspase-10 in innate immune responses to double-stranded
RNA. J Immunol 2006;176:4520–4524.
74. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of
Drosophila, required for dorsal-ventral embryonic polarity,
appears to encode a transmembrane protein. Cell 1988;52:269–279.
75. Gay NJ, Keith FJ. Drosophila Toll and IL-1 receptor.
Nature 1991;351:355–356.
76. Brightbill HD, Libraty DH, Krutzik SR, et al. Host
defense mechanisms triggered by microbial lipoproteins through
Toll-like receptors. Science 1999;285:732–736.
77. Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral
regulatory gene cassette spatzle/Toll/cactus controls the potent
antifungal response in Drosophila adults. Cell 1996;86:973–983.
78. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A
human homologue of the Drosophila Toll protein signals activa-
tion of adaptive immunity. Nature 1997;388:394–397.
79. Takeuchi O, Hoshino K, Kawai T, et al. Differential roles
of TLR2 and TLR4 in recognition of gram-negative and gram-
positive bacterial cell wall components. Immunity 1999;11:443–
451.
80. Horng T, Barton GM, Medzhitov R. TIRAP: An adapter
molecule in the Toll signaling pathway. Nat Immunol 2001;2:
835–841.
81. Jenkins KA, Mansell A. TIR-containing adaptors in Toll-
like receptor signalling. Cytokine 2010;49:237–244.
82. Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88
is an adaptor protein in the hToll/IL-1 receptor family signaling
pathways. Mol Cell 1998;2:253–258.
83. O’Neill LA, Bowie AG. The family of five: TIR-domain-
containing adaptors in Toll-like receptor signalling. Nat Rev
Immunol 2007;7:353–364.
84. West AP, Koblansky AA, Ghosh S. Recognition and sig-
naling by Toll-like receptors. Annu Rev Cell Dev Biol
2006;22:409–437.
85. Kawagoe T, Sato S, Matsushita K, et al. Sequential con-
trol of Toll-like receptor-dependent responses by IRAK1 and
IRAK2. Nat Immunol 2008;9:684–691.
86. Sato S, Sanjo H, Takeda K, et al. Essential function for
the kinase TAK1 in innate and adaptive immune responses. Nat
Immunol 2005;6:1087–1095.
87. Aksoy E, Vanden Berghe W, Detienne S, et al. Inhibition
of phosphoinositide 3-kinase enhances TRIF-dependent NF-
kappa B activation and IFN-beta synthesis downstream of Toll-
like receptor 3 and 4. Eur J Immunol 2005;35:2200–2209.
88. Liljeroos M, Vuolteenaho R, Morath S, et al. Bruton’s
tyrosine kinase together with PI 3-kinase are part of Toll-like
receptor 2 multiprotein complex and mediate LTA induced Toll-
like receptor 2 responses in macrophages. Cell Signal 2007;19:
625–633.
89. Ojaniemi M, Glumoff V, Harju K, et al. Phosphatidylino-
sitol 3-kinase is involved in Toll-like receptor 4-mediated cyto-
kine expression in mouse macrophages. Eur J Immunol
2003;33:597–605.
90. Cabanski M, Steinmuller M, Marsh LM, et al. PKR regu-
lates TLR2/TLR4-dependent signaling in murine alveolar macro-
phages. Am J Respir Cell Mol Biol 2008;38:26–31.
91. Lentschat A, Karahashi H, Michelsen KS, et al. Mastopa-
ran, a G protein agonist peptide, differentially modulates TLR4-
and TLR2-mediated signaling in human endothelial cells and
murine macrophages. J Immunol 2005;174:4252–4261.
92. Skokos D, Nussenzweig MC. CD8- DCs induce IL-12-inde-
pendent Th1 differentiation through Delta 4 Notch-like ligand in
response to bacterial LPS. J Exp Med 2007;204:1525–1531.
93. Sabroe I, Parker LC, Dower SK, et al. The role of TLR
activation in inflammation. J Pathol 2008;214:126–135.
94. Aldape MJ, Bryant AE, Katahira EJ, et al. Innate
immune recognition of, and response to, Clostridium sordellii.
Anaerobe 2010;16:125–130.
95. Netea MG, Kullberg BJ, Galama JM, et al. Non-LPS
components of Chlamydia pneumoniae stimulate cytokine produc-
tion through Toll-like receptor 2-dependent pathways. Eur J
Immunol 2002;32:1188–1195.
96. Schwandner R, Dziarski R, Wesche H, et al. Peptidogly-
can- and lipoteichoic acid-induced cell activation is mediated by
toll-like receptor 2. J Biol Chem 1999;274:17406–17409.
97. Zahringer U, Lindner B, Inamura S, et al. TLR2 - promis-
cuous or specific? A critical re-evaluation of a receptor expressing
apparent broad specificity. Immunobiology 2008;213:205–224.
98. Lorne E, Dupont H, Abraham E. Toll-like receptors 2
and 4: Initiators of non-septic inflammation in critical care medi-
cine? Intensive Care Med 2010;36:1826–1835.
99. Takeuchi O, Kawai T, Muhlradt PF, et al. Discrimination
of bacterial lipoproteins by Toll-like receptor 6. Int Immunol
2001;13:933–940.
100. Takeuchi O, Sato S, Horiuchi T, et al. Cutting edge:
Role of Toll-like receptor 1 in mediating immune response to
microbial lipoproteins. J Immunol 2002;169:10–14.
472 Lewis et al
101. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge:
Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to
lipopolysaccharide: Evidence for TLR4 as the Lps gene product.
J Immunol 1999;162:3749–3752.
102. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduc-
tion pathway. Cytokine 2008;42:145–151.
103. Takeda K, Akira S. Toll-like receptors in innate immu-
nity. Int Immunol 2005;17:1–14.
104. Park BS, Song DH, Kim HM, et al. The structural basis
of lipopolysaccharide recognition by the TLR4-MD-2 complex.
Nature 2009;458:1191–1195.
105. Andersen-Nissen E, Smith KD, Bonneau R, et al. A con-
served surface on Toll-like receptor 5 recognizes bacterial flagel-
lin. J Exp Med 2007;204:393–403.
106. Uematsu S, Fujimoto K, Jang MH, et al. Regulation of
humoral and cellular gut immunity by lamina propria dendritic
cells expressing Toll-like receptor 5. Nat Immunol 2008;9:769–776.
107. Liaudet L, Szabo C, Evgenov OV, et al. Flagellin from
Gram-negative bacteria is a potent mediator of acute pulmonary
inflammation in sepsis. Shock 2003;19:131–137.
108. Kumar H, Kawai T, Akira S. Pathogen recognition in
the innate immune response. Biochem J 2009;420:1–16.
109. Herskovits AA, Auerbuch V, Portnoy DA. Bacterial
ligands generated in a phagosome are targets of the cytosolic
innate immune system. PLoS Pathog 2007;3:e51.
110. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor
TRIF in the MyD88-independent Toll-like receptor signaling
pathway. Science 2003;301:640–643.
111. Yarovinsky F, Zhang D, Andersen JF, et al. TLR11 acti-
vation of dendritic cells by a protozoan profilin-like protein. Sci-
ence 2005;308:1626–1629.
112. Zhang D, Zhang G, Hayden MS, et al. A Toll-like recep-
tor that prevents infection by uropathogenic bacteria. Science
2004;303:1522–1526.
113. Carneiro LA, Magalhaes JG, Tattoli I, et al. Nod-like
proteins in inflammation and disease. J Pathol 2008;214:136–148.
114. Chamaillard M, Hashimoto M, Horie Y, et al. An essen-
tial role for NOD1 in host recognition of bacterial peptidoglycan
containing diaminopimelic acid. Nat Immunol 2003;4:702–707.
115. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general
sensor of peptidoglycan through muramyl dipeptide (MDP)
detection. J Biol Chem 2003;278:8869–8872.
116. Jones JD, Dangl JL. The plant immune system. Nature
2006;444:323–329.
117. Kanneganti TD, Lamkanfi M, Nunez G. Intracellular
NOD-like receptors in host defense and disease. Immunity
2007;27:549–559.
118. Franchi L, Warner N, Viani K, et al. Function of
Nod-like receptors in microbial recognition and host defense.
Immunol Rev 2009;227:106–128.
119. Inohara N, Chamaillard M, McDonald C, et al. NOD-
LRR proteins: Role in host-microbial interactions and inflamma-
tory disease. Annu Rev Biochem 2005;74:355–383.
120. Moore CB, Bergstralh DT, Duncan JA, et al. NLRX1 is
a regulator of mitochondrial antiviral immunity. Nature
2008;451:573–577.
121. Barnich N, Aguirre JE, Reinecker HC, et al. Membrane
recruitment of NOD2 in intestinal epithelial cells is essential for
nuclear factor-kappaB activation in muramyl dipeptide recogni-
tion. J Cell Biol 2005;170:21–26.
122. Kufer TA, Kremmer E, Adam AC, et al. The pattern-
recognition molecule Nod1 is localized at the plasma membrane
at sites of bacterial interaction. Cell Microbiol 2008;10:477–486.
123. Marina-Garcia N, Franchi L, Kim YG, et al. Pannexin-
1-mediated intracellular delivery of muramyl dipeptide induces
caspase-1 activation via cryopyrin/NLRP3 independently of
Nod2. J Immunol 2008;180:4050–4057.
124. Ratner AJ, Aguilar JL, Shchepetov M, et al. Nod1 medi-
ates cytoplasmic sensing of combinations of extracellular bacte-
ria. Cell Microbiol 2007;9:1343–1351.
125. Viala J, Chaput C, Boneca IG, et al. Nod1 responds to
peptidoglycan delivered by the Helicobacter pylori cag pathoge-
nicity island. Nat Immunol 2004;5:1166–1174.
126. Hasegawa M, Fujimoto Y, Lucas PC, et al. A critical
role of RICK/RIP2 polyubiquitination in Nod-induced NF-kap-
paB activation. EMBO J 2008;27:373–383.
127. Inohara N, Koseki T, del Peso L, et al. Nod1, an Apaf-
1-like activator of caspase-9 and nuclear factor-kappaB. J Biol
Chem 1999;274:14560–14567.
128. Kim JY, Omori E, Matsumoto K, et al. TAK1 is a cen-
tral mediator of NOD2 signaling in epidermal cells. J Biol Chem
2008;283:137–144.
129. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/
Apaf-1 family member that is restricted to monocytes and acti-
vates NF-kappaB. J Biol Chem 2001;276:4812–4818.
130. Strober W, Watanabe T. NOD2, an intracellular innate
immune sensor involved in host defense and Crohn’s disease.
Mucosal Immunol 2011;4:484–495.
131. Masumoto J, Yang K, Varambally S, et al. Nod1 acts as
an intracellular receptor to stimulate chemokine production and
neutrophil recruitment in vivo. J Exp Med 2006;203:203–213.
132. Cartwright N, Murch O, McMaster SK, et al. Selective
NOD1 agonists cause shock and organ injury/dysfunction in vivo.
Am J Respir Crit Care Med 2007;175:595–603.
133. Lamkanfi M, Dixit VM. Inflammasomes: Guardians of
cytosolic sanctity. Immunol Rev 2009;227:95–105.
134. Lamkanfi M, Dixit VM. The inflammasomes. PLoS Pa-
thog 2009;5:e1000510.
135. Martinon F, Burns K, Tschopp J. The inflammasome: A
molecular platform triggering activation of inflammatory caspas-
es and processing of proIL-beta. Mol Cell 2002;10:417–426.
136. Franchi L, Amer A, Body-Malapel M, et al. Cytosolic fla-
gellin requires Ipaf for activation of caspase-1 and interleukin 1beta
in salmonella-infected macrophages. Nat Immunol 2006;7:576–582.
137. Martinon F, Petrilli V, Mayor A, et al. Gout-associated
uric acid crystals activate the NALP3 inflammasome. Nature
2006;440:237–241.
138. Sutterwala FS, Mijares LA, Li L, et al. Immune recogni-
tion of Pseudomonas aeruginosa mediated by the IPAF/NLRC4
inflammasome. J Exp Med 2007;204:3235–3245.
139. Tsuji NM, Tsutsui H, Seki E, et al. Roles of caspase-1 in
Listeria infection in mice. Int Immunol 2004;16:335–343.
140. Mariathasan S, Weiss DS, Dixit VM, et al. Innate immu-
nity against Francisella tularensis is dependent on the ASC/cas-
pase-1 axis. J Exp Med 2005;202:1043–1049.
141. Sarkar A, Hall MW, Exline M, et al. Caspase-1 regulates
Escherichia coli sepsis and splenic B cell apoptosis independently
of interleukin-1beta and interleukin-18. Am J Respir Crit Care
Med 2006;174:1003–1010.
142. Saleh M, Mathison JC, Wolinski MK, et al. Enhanced
bacterial clearance and sepsis resistance in caspase-12-deficient
mice. Nature 2006;440:1064–1068.
143. Saleh M, Vaillancourt JP, Graham RK, et al. Differential
modulation of endotoxin responsiveness by human caspase-12
polymorphisms. Nature 2004;429:75–79.
144. Li P, Allen H, Banerjee S, et al. Mice deficient in IL-1
beta-converting enzyme are defective in production of mature IL-
1 beta and resistant to endotoxic shock. Cell 1995;80:401–411.
145. Mariathasan S, Newton K, Monack DM, et al. Differen-
tial activation of the inflammasome by caspase-1 adaptors ASC
and Ipaf. Nature 2004;430:213–218.
146. Fahy RJ, Exline MC, Gavrilin MA, et al. Inflammasome
mRNA expression in human monocytes during early septic
shock. Am J Respir Crit Care Med 2008;177:983–988.
Immunopathology of Sepsis 473
147. Kempster SL, Belteki G, Forhead AJ, et al. Developmen-
tal control of the Nlrp6 inflammasome and a substrate, IL-18, in
mammalian intestine. Am J Physiol Gastrointest Liver Physiol
2011;300:G253–G263.
148. Chen H, Li C, Fang M, et al. Understanding Haemophi-
lus parasuis infection in porcine spleen through a transcriptomics
approach. BMC Genomics 2009;10:64.
149. Li R, Zhang A, Chen B, et al. Response of swine spleen
to Streptococcus suis infection revealed by transcription analysis.
BMC Genomics 2010;11:556.
150. Swerdlow MP, Kennedy DR, Kennedy JS, et al. Expres-
sion and function of TLR2, TLR4, and Nod2 in primary canine
colonic epithelial cells. Vet Immunol Immunopathol 2006;114:
313–319.
151. Asahina Y, Yoshioka N, Kano R, et al. Full-length
cDNA cloning of Toll-like receptor 4 in dogs and cats. Vet
Immunol Immunopathol 2003;96:159–167.
152. Hashimoto M, Asahina Y, Sano J, et al. Cloning of
canine Toll-like receptor 9 and its expression in dog tissues. Vet
Immunol Immunopathol 2005;106:159–163.
153. Ishii M, Hashimoto M, Oguma K, et al. Molecular clon-
ing and tissue expression of canine Toll-like receptor 2 (TLR2).
Vet Immunol Immunopathol 2006;110:87–95.
154. Okui Y, Kano R, Maruyama H, et al. Cloning of canine
Toll-like receptor 7 gene and its expression in dog tissues. Vet
Immunol Immunopathol 2008;121:156–160.
155. Franchini M, Zini E, Osto M, et al. Feline pancreatic
islet-like clusters and insulin producing cells express functional
Toll-like receptors (TLRs). Vet Immunol Immunopathol
2010;138:70–78.
156. Lehman TL, O’Halloran KP, Fallon SA, et al. Altered
bone marrow dendritic cell cytokine production to Toll-like
receptor and CD40 ligation during chronic feline immunodefi-
ciency virus infection. Immunology 2009;126:405–412.
157. Kwong LS, Parsons R, Patterson R, et al. Characterisa-
tion of antibodies to bovine Toll-like receptor (TLR)-2 and
cross-reactivity with ovine TLR2. Vet Immunol Immunopathol
2011;139:313–318.
158. Dhanasekaran S, Kannan TA, Dhinakar Raj G, et al.
Differential expression of Toll-like receptor mRNA in corneal
epithelium of ruminants. Vet Ophthalmol 2010;13:270–274.
159. Bridger PS, Mohr M, Stamm I, et al. Primary bovine
colonic cells: A model to study strain-specific responses to Esc-
herichia coli. Vet Immunol Immunopathol 2010;137:54–63.
160. Farhat K, Riekenberg S, Jung G, et al. Identification of
full length bovine TLR1 and functional characterization of lipo-
peptide recognition by bovine TLR2/1 heterodimer. Vet Res
2010;41:34.
161. Seabury CM, Seabury PM, Decker JE, et al. Diversity
and evolution of 11 innate immune genes in Bos taurus taurus
and Bos taurus indicus cattle. Proc Natl Acad Sci USA
2010;107:151–156.
162. Arsenault RJ, Jalal S, Babiuk LA, et al. Kinome analysis
of Toll-like receptor signaling in bovine monocytes. J Recept Sig-
nal Transduct Res 2009;29:299–311.
163. Herath S, Lilly ST, Santos NR, et al. Expression of genes
associated with immunity in the endometrium of cattle with dis-
parate postpartum uterine disease and fertility. Reprod Biol
Endocrinol 2009;7:55.
164. Mucha R, Bhide MR, Chakurkar EB, et al. Toll-like
receptors TLR1, TLR2 and TLR4 gene mutations and natural
resistance to Mycobacterium avium subsp. paratuberculosis infec-
tion in cattle. Vet Immunol Immunopathol 2009;128:381–388.
165. Zhu J, Brownlie R, Liu Q, et al. Characterization of
bovine Toll-like receptor 8: Ligand specificity, signaling essential
sites and dimerization. Mol Immunol 2009;46:978–990.
166. Jann OC, Werling D, Chang JS, et al. Molecular evolu-
tion of bovine Toll-like receptor 2 suggests substitutions of func-
tional relevance. BMC Evol Biol 2008;8:288.
167. Goldammer T, Zerbe H, Molenaar A, et al. Mastitis
increases mammary mRNA abundance of beta-defensin 5, Toll-
like-receptor 2 (TLR2), and TLR4 but not TLR9 in cattle. Clin
Diagn Lab Immunol 2004;11:174–185.
168. Schneberger D, Lewis D, Caldwell S, et al. Expression of
Toll-like receptor 9 in lungs of pigs, dogs and cattle. Int J Exp
Pathol 2011;92:1–7.
169. Jann OC, King A, Corrales NL, et al. Comparative ge-
nomics of Toll-like receptor signalling in five species. BMC Ge-
nomics 2009;10:216.
170. Mikula I Jr, Mikula I Sr, Characterization of ovine Toll-
like receptor 9 protein coding region, comparative analysis, detec-
tion of mutations and maedi visna infection. Dev Comp Immu-
nol 2011;35:182–192.
171. Plain KM, Purdie AC, Begg DJ, et al. Toll-like receptor
(TLR)6 and TLR1 differentiation in gene expression studies of
Johne’s disease. Vet Immunol Immunopathol 2010;137:142–148.
172. Byun SO, Zhou H, Hickford JG. Development of a sim-
ple typing method for the ovine Toll-like receptor 4 gene. Vet
Immunol Immunopathol 2009;130:272–274.
173. Hillman NH, Moss TJ, Nitsos I, et al. Toll-like receptors
and agonist responses in the developing fetal sheep lung. Pediatr
Res 2008;63:388–393.
174. Raja A, Vignesh AR, Mary BA, et al. Sequence analysis
of Toll-like receptor genes 1-10 of goat (Capra hircus). Vet
Immunol Immunopathol 2011;140:252–258.
175. Tourais-Esteves I, Bernardet N, Lacroix-Lamande S,
et al. Neonatal goats display a stronger TH1-type cytokine
response to TLR ligands than adults. Dev Comp Immunol
2008;32:1231–1241.
176. Gornik K, Moore P, Figueiredo M, et al. Expression of
Toll-like receptors 2, 3, 4, 6, 9, and MD-2 in the normal
equine cornea, limbus, and conjunctiva. Vet Ophthalmol
2011;14:80–85.
177. Kwon S, Vandenplas ML, Figueiredo MD, et al. Differ-
ential induction of Toll-like receptor gene expression in equine
monocytes activated by Toll-like receptor ligands or TNF-alpha.
Vet Immunol Immunopathol 2010;138:213–217.
178. Berndt A, Derksen FJ, Venta PJ, et al. Elevated amount
of Toll-like receptor 4 mRNA in bronchial epithelial cells is asso-
ciated with airway inflammation in horses with recurrent airway
obstruction. Am J Physiol Lung Cell Mol Physiol 2007;292:
L936–943.
179. Singh Suri S, Janardhan KS, Parbhakar O, et al. Expres-
sion of Toll-like receptor 4 and 2 in horse lungs. Vet Res
2006;37:541–551.
180. Werners AH, Bull S, Vendrig JC, et al. Genotyping of
Toll-like receptor 4, myeloid differentiation factor 2 and CD-14
in the horse: An investigation into the influence of genetic poly-
morphisms on the LPS induced TNF-alpha response in equine
whole blood. Vet Immunol Immunopathol 2006;111:165–173.
181. Schneberger D, Caldwell S, Suri SS, et al. Expression of
Toll-like receptor 9 in horse lungs. Anat Rec (Hoboken)
2009;292:1068–1077.
182. Uenishi H, Shinkai H, Morozumi T, et al. Polymorphisms
in pattern recognition receptors and their relationship to infectious
disease susceptibility in pigs. BMC Proc 2011;5(Suppl 4):S27.
183. Shinkai H, Suzuki R, Akiba M, et al. Porcine Toll-like
receptors: Recognition of Salmonella enterica serovar Cholerae-
suis and influence of polymorphisms. Mol Immunol 2011;48:
1114–1120.
184. Evren S, Loai Y, Antoon R, et al. Urinary bladder tissue
engineering using natural scaffolds in a porcine model: Role of
474 Lewis et al
Toll-like receptors and impact of biomimetic molecules. Cells Tis-
sues Organs 2010;192:250–261.
185. Auray G, Facci MR, van Kessel J, et al. Differential acti-
vation and maturation of two porcine DC populations following
TLR ligand stimulation. Mol Immunol 2010;47:2103–2111.
186. Morozumi T, Uenishi H. Polymorphism distribution and
structural conservation in RNA-sensing Toll-like receptors 3, 7,
and 8 in pigs. Biochim Biophys Acta 2009;1790:267–274.
187. Toka FN, Nfon CK, Dawson H, et al. Accessory-cell-
mediated activation of porcine NK cells by Toll-like receptor 7
(TLR7) and TLR8 agonists. Clin Vaccine Immunol 2009;16:866–
878.
188. Burkey TE, Skjolaas KA, Dritz SS, et al. Expression of
porcine Toll-like receptor 2, 4 and 9 gene transcripts in the pres-
ence of lipopolysaccharide and Salmonella enterica serovars Ty-
phimurium and Choleraesuis. Vet Immunol Immunopathol
2009;130:96–101.
189. Liu CH, Chaung HC, Chang HL, et al. Expression of
Toll-like receptor mRNA and cytokines in pigs infected with por-
cine reproductive and respiratory syndrome virus. Vet Microbiol
2009;136:266–276.
190. Chaung HC, Chen CW, Hsieh BL, et al. Toll-like recep-
tor expressions in porcine alveolar macrophages and dendritic
cells in responding to poly IC stimulation and porcine reproduc-
tive and respiratory syndrome virus (PRRSV) infection. Comp
Immunol Microbiol Infect Dis 2010;33:197–213.
191. Uenishi H, Shinkai H. Porcine Toll-like receptors: The
front line of pathogen monitoring and possible implications for
disease resistance. Dev Comp Immunol 2009;33:353–361.
192. Ibeagha-Awemu EM, Lee JW, Ibeagha AE, et al. Bacte-
rial lipopolysaccharide induces increased expression of Toll-like
receptor (TLR) 4 and downstream TLR signaling molecules in
bovine mammary epithelial cells. Vet Res 2008;39:11.
193. Worku M, Morris A. Binding of different forms of lipo-
polysaccharide and gene expression in bovine blood neutrophils.
J Dairy Sci 2009;92:3185–3193.
194. Cates EA, Connor EE, Mosser DM, et al. Functional
characterization of bovine TIRAP and MyD88 in mediating bac-
terial lipopolysaccharide-induced endothelial NF-kappaB activa-
tion and apoptosis. Comp Immunol Microbiol Infect Dis
2009;32:477–490.
195. Gil LH, van Olphen AL, Mittal SK, et al. Modulation of
PKR activity in cells infected by bovine viral diarrhea virus.
Virus Res 2006;116:69–77.
196. Sen A, Pruijssers AJ, Dermody TS, et al. The early inter-
feron response to rotavirus is regulated by PKR and depends on
MAVS/IPS-1, RIG-I, MDA-5, and IRF3. J Virol 2011;85:3717–
3732.
197. Bougarn S, Cunha P, Harmache A, et al. Muramyl
dipeptide synergizes with Staphylococcus aureus lipoteichoic acid
to recruit neutrophils in the mammary gland and to stimulate
mammary epithelial cells. Clin Vaccine Immunol 2010;17:1797–
1809.
198. Whelehan CJ, Meade KG, Eckersall PD, et al. Experi-
mental Staphylococcus aureus infection of the mammary gland
induces region-specific changes in innate immune gene expression.
Vet Immunol Immunopathol 2011;140:181–189.
199. Purdie AC, Plain KM, Begg DJ, et al. Candidate gene
and genome-wide association studies of Mycobacterium avium
subsp. paratuberculosis infection in cattle and sheep: A review.
Comp Immunol Microbiol Infect Dis 2011;34:197–208.
200. Fenhammar J, Rundgren M, Forestier J, et al. Toll-like
receptor 4 inhibitor TAK-242 attenuates acute kidney injury in
endotoxemic sheep. Anesthesiology 2011;114:1130–1137.
201. Alvarez B, Revilla C, Chamorro S, et al. Molecular clon-
ing, characterization and tissue expression of porcine Toll-like
receptor 4. Dev Comp Immunol 2006;30:345–355.
202. Alves MP, Neuhaus V, Guzylack-Piriou L, et al. Toll-
like receptor 7 and MyD88 knockdown by lentivirus-mediated
RNA interference to porcine dendritic cell subsets. Gene Ther
2007;14:836–844.
203. Moue M, Tohno M, Shimazu T, et al. Toll-like receptor
4 and cytokine expression involved in functional immune
response in an originally established porcine intestinal epithelio-
cyte cell line. Biochim Biophys Acta 2008;1780:134–144.
204. Muneta Y, Uenishi H, Kikuma R, et al. Porcine TLR2
and TLR6: Identification and their involvement in Mycoplasma
hyopneumoniae infection. J Interferon Cytokine Res 2003;23:583–
590.
205. Shimosato T, Kitazawa H, Katoh S, et al. Swine Toll-
like receptor 9(1) recognizes CpG motifs of human cell stimulant.
Biochim Biophys Acta 2003;1627:56–61.
206. Shinkai H, Tanaka M, Morozumi T, et al. Biased distri-
bution of single nucleotide polymorphisms (SNPs) in porcine
Toll-like receptor 1 (TLR1), TLR2, TLR4, TLR5, and TLR6
genes. Immunogenetics 2006;58:324–330.
207. Shinkai H, Muneta Y, Suzuki K, et al. Porcine Toll-like
receptor 1, 6, and 10 genes: Complete sequencing of genomic
region and expression analysis. Mol Immunol 2006;43:1474–
1480.
208. Thomas AV, Broers AD, Vandegaart HF, et al. Genomic
structure, promoter analysis and expression of the porcine (Sus
scrofa) TLR4 gene. Mol Immunol 2006;43:653–659.
209. Wassef A, Janardhan K, Pearce JW, et al. Toll-like
receptor 4 in normal and inflamed lungs and other organs of pig,
dog and cattle. Histol Histopathol 2004;19:1201–1208.
210. Miguel JC, Chen J, Van Alstine WG, et al. Expression of
inflammatory cytokines and Toll-like receptors in the brain and
respiratory tract of pigs infected with porcine reproductive and
respiratory syndrome virus. Vet Immunol Immunopathol
2010;135:314–319.
211. Sang Y, Yang J, Ross CR, et al. Molecular identification
and functional expression of porcine Toll-like receptor (TLR) 3
and TLR7. Vet Immunol Immunopathol 2008;125:162–167.
212. Jozaki K, Shinkai H, Tanaka-Matsuda M, et al. Influ-
ence of polymorphisms in porcine NOD2 on ligand recognition.
Mol Immunol 2009;47:247–252.
213. Kojima-Shibata C, Shinkai H, Morozumi T, et al. Differ-
ences in distribution of single nucleotide polymorphisms among
intracellular pattern recognition receptors in pigs. Immunogenet-
ics 2009;61:153–160.
214. Luo R, Xiao S, Jiang Y, et al. Porcine reproductive and
respiratory syndrome virus (PRRSV) suppresses interferon-beta
production by interfering with the RIG-I signaling pathway. Mol
Immunol 2008;45:2839–2846.
215. Tohno M, Shimazu T, Aso H, et al. Molecular cloning
and functional characterization of porcine nucleotide-binding
oligomerization domain-1 (NOD1) recognizing minimum agon-
ists, meso-diaminopimelic acid and meso-lanthionine. Mol Immu-
nol 2008;45:1807–1817.
216. Tohno M, Ueda W, Azuma Y, et al. Molecular cloning
and functional characterization of porcine nucleotide-binding olig-
omerization domain-2 (NOD2). Mol Immunol 2008;45:194–203.
217. Tohno M, Shimazu T, Aso H, et al. Molecular cloning
and functional characterization of porcine MyD88 essential for
TLR signaling. Cell Mol Immunol 2007;4:369–376.
218. Kwon S, Gewirtz AT, Hurley DJ, et al. Disparities in
TLR5 expression and responsiveness to flagellin in equine neutroph-
ils andmononuclear phagocytes. J Immunol 2011;186:6263–6270.
219. Gold JR, Perkins GA, Erb HN, et al. Cytokine profiles
of peripheral blood mononuclear cells isolated from septic and
healthy neonatal foals. J Vet Intern Med 2007;21:482–488.
220. Lopes MA, Salter CE, Vandenplas ML, et al. Expression
of inflammation-associated genes in circulating leukocytes
Immunopathology of Sepsis 475
collected from horses with gastrointestinal tract disease. Am J
Vet Res 2010;71:915–924.
221. Menzies-Gow NJ, Bailey SR, Stevens K, et al. Digital
blood flow and plasma endothelin concentration in clinically en-
dotoxemic horses. Am J Vet Res 2005;66:630–636.
222. Figueiredo MD, Vandenplas ML, Hurley DJ, et al. Dif-
ferential induction of MyD88- and TRIF-dependent pathways in
equine monocytes by Toll-like receptor agonists. Vet Immunol
Immunopathol 2009;127:125–134.
223. Allenspach K, House A, Smith K, et al. Evaluation of
mucosal bacteria and histopathology, clinical disease activity and
expression of Toll-like receptors in German Shepherd Dogs with
chronic enteropathies. Vet Microbiol 2010;146:326–335.
224. Tian X, Pascal G, Monget P. Evolution and functional
divergence of NLRP genes in mammalian reproductive systems.
BMC Evol Biol 2009;9:202.
225. Burgener IA, Jungi TW. Antibodies specific for human
or murine Toll-like receptors detect canine leukocytes by flow
cytometry. Vet Immunol Immunopathol 2008;124:184–191.
226. Chotimanukul S, Sirivaidyapong S. Differential expres-
sion of Toll-like receptor 4 (TLR4) in healthy and infected canine
endometrium. Theriogenology 2011;76:1152–1161.
227. Abujamra AL, Spanjaard RA, Akinsheye I, et al. Leuke-
mia virus long terminal repeat activates NFkappaB pathway by a
TLR3-dependent mechanism. Virology 2006;345:390–403.
228. Burgener IA, Konig A, Allenspach K, et al. Upregula-
tion of Toll-like receptors in chronic enteropathies in dogs. J Vet
Intern Med 2008;22:553–560.
229. House AK, Binns MM, Gregory SP, et al. Analysis of
NOD1, NOD2, TLR1, TLR2, TLR4, TLR5, TLR6 and TLR9
genes in anal furunculosis of German Shepherd Dogs. Tissue
Antigens 2009;73:250–254.
230. Kathrani A, House A, Catchpole B, et al. Polymor-
phisms in the TLR4 and TLR5 gene are significantly associated
with inflammatory bowel disease in German Shepherd Dogs.
PLoS ONE 2010;5:e15740.
231. Kathrani A, House A, Catchpole B, et al. Breed-indepen-
dent Toll-like receptor 5 polymorphisms show association with
canine inflammatoryboweldisease.TissueAntigens 2011;78:94–101.
232. Mikula I, Bhide M, Pastorekova S. Characterization of
ovine TLR7 and TLR8 protein coding regions, detection of
mutations and Maedi Visna virus infection. Vet Immunol Immu-
nopathol 2010;138:51–59.
233. McCullough KC, Summerfield A. Targeting the porcine
immune system–particulate vaccines in the 21st century. Dev
Comp Immunol 2009;33:394–409.
234. Li J, Birkenheuer AJ, Marr HS, et al. Expression and
function of triggering receptor expressed on myeloid cells-1
(TREM-1) on canine neutrophils. Dev Comp Immunol
2011;35:872–880.
235. Derive M, Massin F, Gibot S. Triggering receptor
expressed on myeloid cells-1 as a new therapeutic target during
inflammatory diseases. Self Nonself 2010;1:225–230.
236. Zhu J, Mohan C. Toll-like receptor signaling pathways–
therapeutic opportunities. Mediators Inflamm 2010;2010:781235.
237. Yamamoto M, Takeda K. Current views of Toll-like
receptor signaling pathways. Gastroenterol Res Pract
2010;2010:240365.
238. Lin Q, Li M, Fang D, et al. The essential roles of Toll-
like receptor signaling pathways in sterile inflammatory diseases.
Int Immunopharmacol 2011;11:1422–1432.
239. Damas P, Reuter A, Gysen P, et al. Tumor necrosis fac-
tor and interleukin-1 serum levels during severe sepsis in humans.
Crit Care Med 1989;17:975–978.
240. Girardin E, Grau GE, Dayer JM, et al. Tumor necrosis
factor and interleukin-1 in the serum of children with severe
infectious purpura. N Engl J Med 1988;319:397–400.
241. Basoglu A, Sen I, Sevinc M, et al. Serum concentrations
of tumor necrosis factor-alpha in neonatal calves with presumed
septicemia. J Vet Intern Med 2004;18:238–241.
242. Otto CM, Drobatz KJ, Soter C. Endotoxemia and tumor
necrosis factor activity in dogs with naturally occurring parvovi-
ral enteritis. J Vet Intern Med 1997;11:65–70.
243. Bradley JR. TNF-mediated inflammatory disease. J
Pathol 2008;214:149–160.
244. Naude PJ, den Boer JA, Luiten PG, et al. Tumor necro-
sis factor receptor cross-talk. FEBS J 2011;278:888–898.
245. Vinay DS, Kwon BS. The tumour necrosis factor/TNF
receptor superfamily: Therapeutic targets in autoimmune dis-
eases. Clin Exp Immunol 2011;164:145–157.
246. Micheau O, Lens S, Gaide O, et al. NF-kappaB signals
induce the expression of c-FLIP. Mol Cell Biol 2001;21:5299–
5305.
247. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing:
the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF
for signaling by the 55-kDa TNF receptor. J Biol Chem
1993;268:18542–18548.
248. Mark KS, Trickler WJ, Miller DW. Tumor necrosis fac-
tor-alpha induces cyclooxygenase-2 expression and prostaglandin
release in brain microvessel endothelial cells. J Pharmacol Exp
Ther 2001;297:1051–1058.
249. Pober JS, Bevilacqua MP, Mendrick DL, et al. Two dis-
tinct monokines, interleukin 1 and tumor necrosis factor, each
independently induce biosynthesis and transient expression of the
same antigen on the surface of cultured human vascular endothe-
lial cells. J Immunol 1986;136:1680–1687.
250. Munro JM, Pober JS, Cotran RS. Tumor necrosis factor
and interferon-gamma induce distinct patterns of endothelial acti-
vation and associated leukocyte accumulation in skin of Papio
anubis. Am J Pathol 1989;135:121–133.
251. Sakaue Y, Nezu Y, Yanagisawa S, et al. Effects of con-
tinuous low-dose infusion of lipopolysaccharide on expression of
E-selectin and intercellular adhesion molecule-1 messenger RNA
and neutrophil accumulation in specific organs in dogs. Am J
Vet Res 2005;66:1259–1266.
252. Miyamoto T, Fujinaga T, Yamashita K, et al. Changes
of serum cytokine activities and other parameters in dogs with
experimentally induced endotoxic shock. Jpn J Vet Res
1996;44:107–118.
253. LeMay DR, LeMay LG, Kluger MJ, et al. Plasma pro-
files of IL-6 and TNF with fever-inducing doses of lipopolysac-
charide in dogs. Am J Physiol 1990;259:R126–132.
254. Otto CM, Rawlings CA. Tumor necrosis factor produc-
tion in cats in response to lipopolysaccharide: An in vivo and in
vitro study. Vet Immunol Immunopathol 1995;49:183–188.
255. MacKay RJ, Merritt AM, Zertuche JM, et al. Tumor
necrosis factor activity in the circulation of horses given endo-
toxin. Am J Vet Res 1991;52:533–538.
256. Nieto JE, MacDonald MH, Braim AE, et al. Effect of
lipopolysaccharide infusion on gene expression of inflammatory
cytokines in normal horses in vivo. Equine Vet J 2009;41:717–719.
257. MacKay RJ, Lester GD. Induction of the acute-phase
cytokine, hepatocyte-stimulating factor/interleukin 6, in the circu-
lation of horses treated with endotoxin. Am J Vet Res
1992;53:1285–1289.
258. Huang H, Lavoie-Lamoureux A, Moran K, et al. IL-4
stimulates the expression of CXCL-8, E-selectin, VEGF, and
inducible nitric oxide synthase mRNA by equine pulmonary
artery endothelial cells. Am J Physiol Lung Cell Mol Physiol
2007;292:L1147–1154.
259. Barton MH, Collatos C. Tumor necrosis factor and
interleukin-6 activity and endotoxin concentration in peritoneal
fluid and blood of horses with acute abdominal disease. J Vet
Intern Med 1999;13:457–464.
476 Lewis et al
260. Stich AN, DeClue AE. Pathogen associated molecular
pattern-induced TNF, IL-1beta, IL-6 and CXCL-8 production
from feline whole blood culture. Res Vet Sci 2011;90:59–63.
261. Osterbur K, Whitehead Z, Sharp CR, et al. Plasma
nitrate/nitrite concentrations in dogs with naturally developing
sepsis and non-infectious forms of the systemic inflammatory
response syndrome. Vet Rec 2011;169:554.
262. LeBlanc CJ, Horohov DW, Bauer JE, et al. Effects of
dietary supplementation with fish oil on in vivo production of
inflammatory mediators in clinically normal dogs. Am J Vet Res
2008;69:486–493.
263. Bevilacqua MP, Pober JS, Majeau GR, et al. Recombi-
nant tumor necrosis factor induces procoagulant activity in cul-
tured human vascular endothelium: Characterization and
comparison with the actions of interleukin 1. Proc Natl Acad Sci
USA 1986;83:4533–4537.
264. Cartwright N, McMaster SK, Sorrentino R, et al. Eluci-
dation of Toll-like receptor and adapter protein signaling in vas-
cular dysfunction induced by gram-positive Staphylococcus
aureus or gram-negative Escherichia coli. Shock 2007;27:40–47.
265. Jimenez R, Belcher E, Sriskandan S, et al. Role of Toll-
like receptors 2 and 4 in the induction of cyclooxygenase-2 in vas-
cular smooth muscle. Proc Natl Acad Sci USA 2005;102:4637–
4642.
266. Schouten M, Wiersinga WJ, Levi M, et al. Inflammation,
endothelium, and coagulation in sepsis. J Leukoc Biol
2008;83:536–545.
267. Cavaillon JM, Adib-Conquy M, Fitting C, et al. Cyto-
kine cascade in sepsis. Scand J Infect Dis 2003;35:535–544.
268. Dinarello CA. Proinflammatory and anti-inflammatory
cytokines as mediators in the pathogenesis of septic shock. Chest
1997;112:321S–329S.
269. Stylianou E, Saklatvala J. Interleukin-1. Int J Biochem
Cell Biol 1998;30:1075–1079.
270. Chaitanya GV, Franks SE, Cromer W, et al. Differen-
tial cytokine responses in human and mouse lymphatic endo-
thelial cells to cytokines in vitro. Lymphat Res Biol 2010;8:
155–164.
271. Dinarello CA. A clinical perspective of IL-1beta as the
gatekeeper of inflammation. Eur J Immunol 2011;41:1203–1217.
272. Jawa RS, Anillo S, Huntoon K, et al. Analytic review:
Interleukin-6 in surgery, trauma, and critical care: Part I: Basic
science. J Intensive Care Med 2011;26:3–12.
273. Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro-
and anti-inflammatory properties of the cytokine interleukin-6.
Biochim Biophys Acta 2011;1813:878–888.
274. Borrelli E, Roux-Lombard P, Grau GE, et al. Plasma
concentrations of cytokines, their soluble receptors, and antioxi-
dant vitamins can predict the development of multiple organ fail-
ure in patients at risk. Crit Care Med 1996;24:392–397.
275. Remick DG, Bolgos GR, Siddiqui J, et al. Six at six:
Interleukin-6 measured 6 h after the initiation of sepsis predicts
mortality over 3 days. Shock 2002;17:463–467.
276. Burton AB, Wagner B, Erb HN, et al. Serum interleu-
kin-6 (IL-6) and IL-10 concentrations in normal and septic neo-
natal foals. Vet Immunol Immunopathol 2009;132:122–128.
277. Scumpia PO, Moldawer LL. Biology of interleukin-10
and its regulatory roles in sepsis syndromes. Crit Care Med
2005;33:S468–S471.
278. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-
10: A complex role in the pathogenesis of sepsis syndromes and
its potential as an anti-inflammatory drug. Crit Care Med
2002;30:S58–S63.
279. Seitz M, Loetscher P, Dewald B, et al. Interleukin-10 dif-
ferentially regulates cytokine inhibitor and chemokine release
from blood mononuclear cells and fibroblasts. Eur J Immunol
1995;25:1129–1132.
280. Kusske AM, Rongione AJ, Ashley SW, et al. Interleu-
kin-10 prevents death in lethal necrotizing pancreatitis in mice.
Surgery 1996;120:284–288; discussion 289.
281. Briassoulis G, Venkataraman S, Thompson A. Cytokines
and metabolic patterns in pediatric patients with critical illness.
Clin Dev Immunol 2010;2010:354047.
282. Pusterla N, Magdesian KG, Mapes S, et al. Expression
of molecular markers in blood of neonatal foals with sepsis. Am
J Vet Res 2006;67:1045–1049.
283. Kipar A, Meli ML, Failing K, et al. Natural feline coro-
navirus infection: Differences in cytokine patterns in association
with the outcome of infection. Vet Immunol Immunopathol
2006;112:141–155.
284. Gao L, Flores C, Fan-Ma S, et al. Macrophage migra-
tion inhibitory factor in acute lung injury: Expression, biomarker,
and associations. Transl Res 2007;150:18–29.
285. Calandra T, Roger T. Macrophage migration inhibitory
factor: A regulator of innate immunity. Nat Rev Immunol
2003;3:791–800.
286. Bozza M, Satoskar AR, Lin G, et al. Targeted disruption
of migration inhibitory factor gene reveals its critical role in sep-
sis. J Exp Med 1999;189:341–346.
287. Brenner T, Hofer S, Rosenhagen C, et al. Macrophage
migration inhibitory factor (MIF) and manganese superoxide
dismutase (MnSOD) as early predictors for survival in patients
with severe sepsis or septic shock. J Surg Res 2010;164:e163–
171.
288. Mitchell RA, Liao H, Chesney J, et al. Macrophage
migration inhibitory factor (MIF) sustains macrophage proinflam-
matory function by inhibiting p53: Regulatory role in the innate
immune response. Proc Natl Acad Sci USA 2002;99:345–350.
289. Stros M. HMGB proteins: Interactions with DNA and
chromatin. Biochim Biophys Acta 2010;1799:101–113.
290. Yang H, Tracey KJ. Targeting HMGB1 in inflammation.
Biochim Biophys Acta 2010;1799:149–156.
291. van Zoelen MA, Yang H, Florquin S, et al. Role of
Toll-like receptors 2 and 4, and the receptor for advanced glyca-
tion end products in high-mobility group box 1-induced inflam-
mation in vivo. Shock 2009;31:280–284.
292. Huang W, Tang Y, Li L. HMGB1, a potent proinflam-
matory cytokine in sepsis. Cytokine 2010;51:119–126.
293. Mitola S, Belleri M, Urbinati C, et al. Cutting edge:
Extracellular high mobility group box-1 protein is a proangiogen-
ic cytokine. J Immunol 2006;176:12–15.
294. Yu DH, Nho DH, Song RH, et al. High-mobility group
box 1 as a surrogate prognostic marker in dogs with systemic
inflammatory response syndrome. J Vet Emerg Crit Care (San
Antonio) 2010;20:298–302.
295. Karlsson S, Pettila V, Tenhunen J, et al. HMGB1 as a
predictor of organ dysfunction and outcome in patients with
severe sepsis. Intensive Care Med 2008;34:1046–1053.
296. de Jong HK, van der Poll T, Wiersinga WJ. The systemic
pro-inflammatory response in sepsis. J Innate Immun 2010;2:422–
430.
297. Cray C, Zaias J, Altman NH. Acute phase response in
animals: A review. Comp Med 2009;59:517–526.
298. Moshage H. Cytokines and the hepatic acute phase
response. J Pathol 1997;181:257–266.
299. Gruys E, Toussaint MJ, Niewold TA, et al. Acute phase
reaction and acute phase proteins. J Zhejiang Univ Sci B
2005;6:1045–1056.
300. Ceciliani F, Giordano A, Spagnolo V. The systemic reac-
tion during inflammation: The acute-phase proteins. Protein Pept
Lett 2002;9:211–223.
301. Noursadeghi M, Pepys MB, Gallimore R, et al. Relation-
ship of granulocyte colony stimulating factor with other acute
phase reactants in man. Clin Exp Immunol 2005;140:97–100.
Immunopathology of Sepsis 477
302. Ceron JJ, Eckersall PD, Martynez-Subiela S. Acute phase
proteins in dogs and cats: Current knowledge and future perspec-
tives. Vet Clin Pathol 2005;34:85–99.
303. Eckersall PD, Bell R. Acute phase proteins: Biomarkers
of infection and inflammation in veterinary medicine. Vet J
2010;185:23–27.
304. Kjelgaard-Hansen M, Jacobsen S. Assay validation and
diagnostic applications of major acute-phase protein testing in
companion animals. Clin Lab Med 2011;31:51–70.
305. Tvarijonaviciute A, Eralp O, Kocaturk M, et al. Adipo-
nectin and IGF-1 are negative acute phase proteins in a dog
model of acute endotoxaemia. Vet Immunol Immunopathol
2011;140:147–151.
306. Castelli GP, Pognani C, Meisner M, et al. Procalcitonin
and C-reactive protein during systemic inflammatory response
syndrome, sepsis and organ dysfunction. Crit Care 2004;8:R234–
R242.
307. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnos-
tic value of procalcitonin, interleukin-6, and interleukin-8 in criti-
cally ill patients admitted with suspected sepsis. Am J Respir Crit
Care Med 2001;164:396–402.
308. Kuzi S, Aroch I, Peleg K, et al. Canine procalcitonin
messenger RNA expression. J Vet Diagn Invest 2008;20:629–633.
309. Giunti M, Peli A, Battilani M, et al. Evaluation of
CALC-I gene (CALCA) expression in tissues of dogs with signs
of the systemic inflammatory response syndrome. J Vet Emerg
Crit Care (San Antonio) 2010;20:523–527.
310. Mukorera V, Dvir E, van der Merwe LL, et al. Serum
C-reactive protein concentration in benign and malignant canine
spirocercosis. J Vet Intern Med 2011;25:963–966.
311. Koster LS, Van Schoor M, Goddard A, et al. C-reactive
protein in canine babesiosis caused by Babesia rossi and its asso-
ciation with outcome. J S Afr Vet Assoc 2009;80:87–91.
312. Sheahan D, Bell R, Mellanby RJ, et al. Acute phase pro-
tein concentrations in dogs with nasal disease. Vet Rec
2010;167:895–899.
313. Lowrie M, Penderis J, Eckersall PD, et al. The role of
acute phase proteins in diagnosis and management of steroid-
responsive meningitis arteritis in dogs. Vet J 2009;182:125–130.
314. Griebsch C, Arndt G, Raila J, et al. C-reactive protein
concentration in dogs with primary immune-mediated hemolytic
anemia. Vet Clin Pathol 2009;38:421–425.
315. Mitchell KD, Kruth SA, Wood RD, et al. Serum acute
phase protein concentrations in dogs with autoimmune hemolytic
anemia. J Vet Intern Med 2009;23:585–591.
316. Bathen-Noethen A, Carlson R, Menzel D, et al. Concen-
trations of acute-phase proteins in dogs with steroid responsive
meningitis-arteritis. J Vet Intern Med 2008;22:1149–1156.
317. Nakamura M, Takahashi M, Ohno K, et al. C-reactive
protein concentration in dogs with various diseases. J Vet Med
Sci 2008;70:127–131.
318. Ohno K, Yokoyama Y, Nakashima K, et al. C-reactive
protein concentration in canine idiopathic polyarthritis. J Vet
Med Sci 2006;68:1275–1279.
319. Dabrowski R, Wawron W, Kostro K. Changes in CRP,
SAA and haptoglobin produced in response to ovariohysterecto-
my in healthy bitches and those with pyometra. Theriogenology
2007;67:321–327.
320. Planellas M, Bassols A, Siracusa C, et al. Evaluation of
serum haptoglobin and C-reactive protein in dogs with mammary
tumors. Vet Clin Pathol 2009;38:348–352.
321. Nielsen L, Toft N, Eckersall PD, et al. Serum C-reactive
protein concentration as an indicator of remission status in dogs
with multicentric lymphoma. J Vet Intern Med 2007;21:1231–1236.
322. Caldin M, Tasca S, Carli E, et al. Serum acute phase
protein concentrations in dogs with hyperadrenocorticism with
and without concurrent inflammatory conditions. Vet Clin Pathol
2009;38:63–68.
323. Chan DL, Rozanski EA, Freeman LM. Relationship
among plasma amino acids, C-reactive protein, illness severity, and
outcome in critically ill dogs. J Vet Intern Med 2009;23:559–563.
324. Gebhardt C, Hirschberger J, Rau S, et al. Use of C-reac-
tive protein to predict outcome in dogs with systemic inflamma-
tory response syndrome or sepsis. J Vet Emerg Crit Care (San
Antonio) 2009;19:450–458.
325. van der Poll T, de Boer JD, Levi M. The effect of inflam-
mation on coagulation and vice versa. Curr Opin Infect Dis
2011;24:273–278.
326. Machado FR, Cesar MS. Sepsis, coagulation and antico-
agulants. Endocr Metab Immune Disord Drug Targets
2010;10:204–213.
327. Sun H. The interaction between pathogens and the host
coagulation system. Physiology (Bethesda) 2006;21:281–288.
328. Huisse MG, Pease S, Hurtado-Nedelec M, et al. Leuko-
cyte activation: The link between inflammation and coagulation
during heatstroke. A study of patients during the 2003 heat wave
in Paris. Crit Care Med 2008;36:2288–2295.
329. de Laforcade AM, Freeman LM, Shaw SP, et al. Hemo-
static changes in dogs with naturally occurring sepsis. J Vet
Intern Med 2003;17:674–679.
330. Bentz AI, Palmer JE, Dallap BL, et al. Prospective evalu-
ation of coagulation in critically ill neonatal foals. J Vet Intern
Med 2009;23:161–167.
331. Estrin MA, Wehausen CE, Jessen CR, et al. Disseminated
intravascular coagulation in cats. J Vet Intern Med 2006;20:
1334–1339.
332. Norris CR, Griffey SM, Samii VF. Pulmonary thrombo-
embolism in cats: 29 cases (1987-1997). J Am Vet Med Assoc
1999;215:1650–1654.
333. Lucas WE, Kitzmiller JL. The role of intravascular coag-
ulation in feline endotoxin shock. Surg Gynecol Obstet
1972;134:73–77.
334. DeClue AE, Williams KJ, Sharp C, et al. Systemic
response to low-dose endotoxin infusion in cats. Vet Immunol
Immunopathol 2009;132:167–174.
335. DelGiudice LA, White GA. The role of tissue factor and
tissue factor pathway inhibitor in health and disease states. J Vet
Emerg Crit Care (San Antonio) 2009;19:23–29.
336. Dallap Schaer BL, Epstein K. Coagulopathy of the criti-
cally ill equine patient. J Vet Emerg Crit Care (San Antonio)
2009;19:53–65.
337. Hopper K, Bateman S. An updated view of hemostasis:
Mechanisms of hemostatic dysfuntion associated with sepsis. J
Vet Emerg Crit Car 2005;15:83–91.
338. Pawlinski R, Mackman N. Cellular sources of tissue fac-
tor in endotoxemia and sepsis. Thromb Res 2010;125(Suppl 1):
S70–S73.
339. Stokol T, Daddona JL, Choi B. Evaluation of tissue fac-
tor procoagulant activity on the surface of feline leukocytes in
response to treatment with lipopolysaccharide and heat-inacti-
vated fetal bovine serum. Am J Vet Res 2010;71:623–629.
340. Grunig G, Hulliger C, Winder C, et al. Spontaneous and
lipopolysaccharide-induced expression of procoagulant activity
by equine lung macrophages in comparison with blood mono-
cytes and blood neutrophils. Vet Immunol Immunopathol
1991;29:295–312.
341. Ouellette AL, Evans RJ, Heath MF. Platelets enhance
endotoxin-induced monocyte tissue factor (TF) activity in the
horse. Res Vet Sci 2004;76:31–35.
342. Henry MM, Moore JN. Clinical relevance of monocyte
procoagulant activity in horses with colic. J Am Vet Med Assoc
1991;198:843–848.
478 Lewis et al
343. Aras O, Shet A, Bach RR, et al. Induction of microparti-
cle- and cell-associated intravascular tissue factor in human endo-
toxemia. Blood 2004;103:4545–4553.
344. Soriano AO, Jy W, Chirinos JA, et al. Levels of endo-
thelial and platelet microparticles and their interactions with
leukocytes negatively correlate with organ dysfunction and pre-
dict mortality in severe sepsis. Crit Care Med 2005;33:2540–
2546.
345. Meziani F, Delabranche X, Asfar P, et al. Bench-to-bed-
side review: Circulating microparticles–a new player in sepsis?
Crit Care 2010;14:236.
346. Miyoshi T, Yamashita K, Arai T, et al. The role of
endothelial interleukin-8/NADPH oxidase 1 axis in sepsis. Immu-
nology 2010;131:331–339.
347. Pawlinski R, Pedersen B, Schabbauer G, et al. Role of
tissue factor and protease-activated receptors in a mouse model
of endotoxemia. Blood 2004;103:1342–1347.
348. Rogers CL, Rozanski EA. Von Willebrand factor antigen
concentration indogswith sepsis. JVet InternMed2010;24:229–230.
349. Pantaleon LG, Furr MO, McKenzie HC, et al. Effects of
small- and large-volume resuscitation on coagulation and electro-
lytes during experimental endotoxemia in anesthetized horses. J
Vet Intern Med 2007;21:1374–1379.
350. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and
safety of recombinant human activated protein C for severe sep-
sis. N Engl J Med 2001;344:699–709.
351. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotox-
emia and sepsis mortality reduction by non-anticoagulant acti-
vated protein C. J Exp Med 2007;204:2439–2448.
352. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sep-
sis Campaign guidelines for management of severe sepsis and sep-
tic shock. Intensive Care Med 2004;30:536–555.
353. Dellinger RP, Levy MM, Carlet JM, et al. Surviving
Sepsis Campaign: International guidelines for management of
severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296
–327.
354. Marti-Carvajal AJ, Sola I, Lathyris D, et al. Human
recombinant activated protein C for severe sepsis. Cochrane
Database Syst Rev 2011;4:CD004388.
355. Jackson CV, Bailey BD, Shetler TJ. Pharmacological
profile of recombinant, human activated protein C (LY203638)
in a canine model of coronary artery thrombosis. J Pharmacol
Exp Ther 2000;295:967–971.
356. Burdick MD, Schaub RG. Human protein C induces
anticoagulation and increased fibrinolytic activity in the cat.
Thromb Res 1987;45:413–419.
357. Oehmcke S, Herwald H. Contact system activation in
severe infectious diseases. J Mol Med (Berl) 2010;88:121–126.
358. Frick IM, Bjorck L, Herwald H. The dual role of the
contact system in bacterial infectious disease. Thromb Haemost
2007;98:497–502.
359. Kaplan AP, Ghebrehiwet B. The plasma bradykinin-
forming pathways and its interrelationships with complement.
Mol Immunol 2010;47:2161–2169.
360. Yarovaya GA, Blokhina TB, Neshkova EA. Contact sys-
tem. New concepts on activation mechanisms and bioregulatory
functions. Biochemistry (Mosc) 2002;67:13–24.
361. Rojkjaer R, Schmaier AH. Activation of the plasma kal-
likrein/kinin system on endothelial cell membranes. Immunophar-
macology 1999;43:109–114.
362. Dong JF. Cleavage of ultra-large von Willebrand factor
by ADAMTS-13 under flow conditions. J Thromb Haemost
2005;3:1710–1716.
363. Claus RA, Bockmeyer CL, Sossdorf M, et al. The bal-
ance between von Willebrand factor and its cleaving protease
ADAMTS13: Biomarker in systemic inflammation and develop-
ment of organ failure? Curr Mol Med 2010;10:236–248.
364. Kremer Hovinga JA, Zeerleder S, Kessler P, et al. AD-
AMTS-13, von Willebrand factor and related parameters in severe
sepsis and septic shock. J Thromb Haemost 2007;5:2284–2290.
365. Martin K, Borgel D, Lerolle N, et al. Decreased ADAM-
TS-13 (A disintegrin-like and metalloprotease with thrombospon-
din type 1 repeats) is associated with a poor prognosis in sepsis-
induced organ failure. Crit Care Med 2007;35:2375–2382.
366. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary
deficiency of von Willebrand factor-cleaving protease (ADAM-
TS13) in patients with sepsis-induced disseminated intravascular
coagulation: Its correlation with development of renal failure.
Blood 2006;107:528–534.
367. Adib-Conquy M, Cavaillon JM. Compensatory anti-
inflammatory response syndrome. Thromb Haemost 2009;101:
36–47.
368. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS.
Crit Care Med 1996;24:1125–1128.
369. Ward NS, Casserly B, Ayala A. The compensatory anti-
inflammatory response syndrome (CARS) in critically ill patients.
Clin Chest Med 2008;29:617–625, viii.
370. Osuchowski MF, Welch K, Siddiqui J, et al. Circulating
cytokine/inhibitor profiles reshape the understanding of the
SIRS/CARS continuum in sepsis and predict mortality. J Immu-
nol 2006;177:1967–1974.
371. Mokart D, Capo C, Blache JL, et al. Early postoperative
compensatory anti-inflammatory response syndrome is associated
with septic complications after major surgical trauma in patients
with cancer. Br J Surg 2002;89:1450–1456.
372. Mokart D, Merlin M, Sannini A, et al. Procalcitonin,
interleukin 6 and systemic inflammatory response syndrome
(SIRS): Early markers of postoperative sepsis after major sur-
gery. Br J Anaesth 2005;94:767–773.
373. Neunaber C, Zeckey C, Andruszkow H, et al. Immuno-
modulation in polytrauma and polymicrobial sepsis: Where do
we stand? Recent Pat Inflamm Allergy Drug Discov 2011;5:17–
25.
374. Power C, Fanning N, Redmond HP. Cellular apoptosis
and organ injury in sepsis: A review. Shock 2002;18:197–211.
375. Ward PA. Sepsis, apoptosis and complement. Biochem
Pharmacol 2008;76:1383–1388.
376. Paula Neto HA, Kubes P. Platelets, endothelium and
shear join forces to mislead neutrophils in sepsis. Crit Care
2011;15:103.
377. Alves-Filho JC, Spiller F, Cunha FQ. Neutrophil paraly-
sis in sepsis. Shock 2010;34(Suppl 1):15–21.
378. Delano MJ, Thayer T, Gabrilovich S, et al. Sepsis
induces early alterations in innate immunity that impact mortal-
ity to secondary infection. J Immunol 2011;186:195–202.
379. Ocuin LM, Bamboat ZM, Balachandran VP, et al. Neu-
trophil IL-10 suppresses peritoneal inflammatory monocytes dur-
ing polymicrobial sepsis. J Leukoc Biol 2011;89:423–432.
380. Escoll P, del Fresno C, Garcia L, et al. Rapid up-regu-
lation of IRAK-M expression following a second endotoxin
challenge in human monocytes and in monocytes isolated from
septic patients. Biochem Biophys Res Commun 2003;311:465–
472.
381. Wullaert A, Verstrepen L, Van Huffel S, et al. LIND/
ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-
kappaB activation. J Biol Chem 2007;282:81–90.
382. Wolk K, Docke WD, von Baehr V, et al. Impaired anti-
gen presentation by human monocytes during endotoxin toler-
ance. Blood 2000;96:218–223.
383. Docke WD, Randow F, Syrbe U, et al. Monocyte deacti-
vation in septic patients: Restoration by IFN-gamma treatment.
Nat Med 1997;3:678–681.
384. Tschaikowsky K, Hedwig-Geissing M, Schiele A, et al.
Coincidence of pro- and anti-inflammatory responses in the early
Immunopathology of Sepsis 479
phase of severe sepsis: Longitudinal study of mononuclear histo-
compatibility leukocyte antigen-DR expression, procalcitonin, C-
reactive protein, and changes in T-cell subsets in septic and post-
operative patients. Crit Care Med 2002;30:1015–1023.
385. Wesche DE, Lomas-Neira JL, Perl M, et al. Leukocyte
apoptosis and its significance in sepsis and shock. J Leukoc Biol
2005;78:325–337.
386. Hsieh YC, Athar M, Chaudry IH. When apoptosis meets
autophagy: Deciding cell fate after trauma and sepsis. Trends
Mol Med 2009;15:129–138.
387. Pinheiro da Silva F, Nizet V. Cell death during sepsis:
Integration of disintegration in the inflammatory response to
overwhelming infection. Apoptosis 2009;14:509–521.
388. Levine B, Mizushima N, Virgin HW. Autophagy in
immunity and inflammation. Nature 2011;469:323–335.
389. Giansanti V, Torriglia A, Scovassi AI. Conversation
between apoptosis and autophagy: “Is it your turn or mine?”.
Apoptosis 2011;16:321–333.
390. Watanabe E, Muenzer JT, Hawkins WG, et al. Sepsis
induces extensive autophagic vacuolization in hepatocytes: A
clinical and laboratory-based study. Lab Invest 2009;89:549–561.
391. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: Host
cell death and inflammation. Nat Rev Microbiol 2009;7:99–109.
392. Kepp O, Galluzzi L, Zitvogel L, et al. Pyroptosis A cell
death modality of its kind? Eur J Immunol 2010;40:627–630.
393. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necro-
sis: mechanistic description of dead and dying eukaryotic cells.
Infect Immun 2005;73:1907–1916.
394. Shao W, Yeretssian G, Doiron K, et al. The caspase-1
digestome identifies the glycolysis pathway as a target during
infection and septic shock. J Biol Chem 2007;282:36321–36329.
395. Nakajima Y, Mikami O, Yoshioka M, et al. Involvement
of apoptosis in the endotoxemic lesions of the liver and kidneys
of piglets. J Vet Med Sci 2000;62:621–626.
396. Sato M, Mikami O, Kobayashi M, et al. Apoptosis in
the lymphatic organs of piglets inoculated with classical swine
fever virus. Vet Microbiol 2000;75:1–9.
397. Messmer UK, Briner VA, Pfeilschifter J. Tumor necrosis
factor-alpha and lipopolysaccharide induce apoptotic cell death in
bovine glomerular endothelial cells. Kidney Int 1999;55:2322–2337.
398. Messmer UK, Winkel G, Briner VA, et al. Glucocortic-
oids potently block tumour necrosis factor-alpha- and lipopoly-
saccharide-induced apoptotic cell death in bovine glomerular
endothelial cells upstream of caspase 3 activation. Br J Pharma-
col 1999;127:1633–1640.
399. Sylte MJ, Leite FP, Kuckleburg CJ, et al. Caspase acti-
vation during Haemophilus somnus lipooligosaccharide-mediated
apoptosis of bovine endothelial cells. Microb Pathog 2003;35:285
–291.
400. Kuckleburg CJ, Tiwari R, Czuprynski CJ. Endothelial
cell apoptosis induced by bacteria-activated platelets requires cas-
pase-8 and -9 and generation of reactive oxygen species. Thromb
Haemost 2008;99:363–372.
401. Wohlschlaeger J, Stubbe HD, Schmitz KJ, et al. Roles of
MMP-2/-9 in cardiac dysfunction during early multiple organ fail-
ure in an ovine animal model. Pathol Res Pract 2005;201:809–817.
402. Umeshappa CS, Singh KP, Nanjundappa RH, et al.
Apoptosis and immuno-suppression in sheep infected with blue-
tongue virus serotype-23. Vet Microbiol 2010;144:310–318.
403. Crouser ED, Julian MW, Weinstein DM, et al. Endo-
toxin-induced ileal mucosal injury and nitric oxide dysregulation
are temporally dissociated. Am J Respir Crit Care Med
2000;161:1705–1712.
404. Paillot R, Richard S, Bloas F, et al. Toward a detailed
characterization of feline immunodeficiency virus-specific T cell
immune responses and mediated immune disorders. Vet Immunol
Immunopathol 2005;106:1–14.
405. Rahal L, Garrido AG, Cruz RJ Jr, et al. Fluid replace-
ment with hypertonic or isotonic solutions guided by mixed
venous oxygen saturation in experimental hypodynamic sepsis. J
Trauma 2009;67:1205–1212.
406. Collins AM, Sewell WA, Edwards MR. Immunoglobulin
gene rearrangement, repertoire diversity, and the allergic
response. Pharmacol Ther 2003;100:157–170.
407. Nikolich-Zugich J, Slifka MK, Messaoudi I. The many
important facets of T-cell repertoire diversity. Nat Rev Immunol
2004;4:123–132.
408. Hollander GA, Peterson P. Learning to be tolerant: How
T cells keep out of trouble. J Intern Med 2009;265:541–561.
409. McCaughtry TM, Hogquist KA. Central tolerance: What
have we learned frommice? Semin Immunopathol 2008;30:399–409.
410. Parish IA, Heath WR. Too dangerous to ignore: Self-tol-
erance and the control of ignorant autoreactive T cells. Immunol
Cell Biol 2008;86:146–152.
411. Waldmann H. Tolerance: An overview and perspectives.
Nat Rev Nephrol 2010;6:569–576.
412. Mueller DL. Mechanisms maintaining peripheral toler-
ance. Nat Immunol 2010;11:21–27.
413. Miyara M, Sakaguchi S. Human FoxP3+CD4+ regulatory
T cells: Their knowns and unknowns. Immunol Cell Biol
2011;89:346–351.
414. Sakaguchi S. Regulatory T cells: History and perspective.
Methods Mol Biol 2011;707:3–17.
415. Shevach EM. The resurrection of T cell-mediated sup-
pression. J Immunol 2011;186:3805–3807.
416. Garden OA, Pinheiro D, Cunningham F. All creatures
great and small: Regulatory T cells in mice, humans, dogs and
other domestic animal species. Int Immunopharmacol
2011;11:576–588.
417. Lankford S, Petty C, LaVoy A, et al. Cloning of feline
FOXP3 and detection of expression in CD4+ CD25+ regulatory
T cells. Vet Immunol Immunopathol 2008;122:159–166.
418. Petty CS, Tompkins MB, Tompkins WA. Transforming
growth factor-beta/transforming growth factor-betaRII signaling
may regulate CD4+CD25+ T-regulatory cell homeostasis and sup-
pressor function in feline AIDS lentivirus infection. J Acquir
Immune Defic Syndr 2008;47:148–160.
419. Smithberg SR, Fogle JE, Mexas AM, et al. In vivo deple-
tion of CD4+CD25+ regulatory T cells in cats. J Immunol Meth-
ods 2008;329:81–91.
420. Vahlenkamp TW, Tompkins MB, Tompkins WA. Feline
immunodeficiency virus infection phenotypically and functionally
activates immunosuppressive CD4+CD25+ T regulatory cells. J
Immunol 2004;172:4752–4761.
421. Fogle JE, Tompkins WA, Tompkins MB. CD4+ CD25+ T
regulatory cells from FIV+ cats induce a unique anergic profile in
CD8+ lymphocyte targets. Retrovirology 2010;7:97.
422. Fogle JE, Mexas AM, Tompkins WA, et al. CD4+CD25+
T regulatory cells inhibit CD8+ IFN-gamma production during
acute and chronic FIV infection utilizing a membrane TGF-beta-
dependent mechanism. AIDS Res Hum Retroviruses 2010;26:
201–216.
423. Achleitner A, Clark ME, Bienzle D. T-regulatory cells
infected with feline immunodeficiency virus up-regulate pro-
grammed death-1 (PD-1). Vet Immunol Immunopathol
2011;143:307–313.
424. Biller BJ, Elmslie RE, Burnett RC, et al. Use of FoxP3
expression to identify regulatory T cells in healthy dogs and dogs
with cancer. Vet Immunol Immunopathol 2007;116:69–78.
425. Keppel KE, Campbell KL, Zuckermann FA, et al. Quanti-
tation of canine regulatory T cell populations, serum interleukin-
10 and allergen-specific IgE concentrations in healthy control dogs
and canine atopic dermatitis patients receiving allergen-specific
immunotherapy. Vet Immunol Immunopathol 2008;123:337–344.
480 Lewis et al
426. O’Neill K, Guth A, Biller B, et al. Changes in regulatory
T cells in dogs with cancer and associations with tumor type. J
Vet Intern Med 2009;23:875–881.
427. Horiuchi Y, Tominaga M, Ichikawa M, et al. Increase of
regulatory T cells in the peripheral blood of dogs with metastatic
tumors. Microbiol Immunol 2009;53:468–474.
428. Mizuno T, Suzuki R, Umeki S, et al. Crossreactivity of
antibodies to canine CD25 and Foxp3 and identification of
canine CD4+CD25+Foxp3+ cells in canine peripheral blood. J Vet
Med Sci 2009;71:1561–1568.
429. Abrams VK, Hwang B, Lesnikova M, et al. A novel
monoclonal antibody specific for canine CD25 (P4A10): Selection
and evaluation of canine Tregs. Vet Immunol Immunopathol
2010;135:257–265.
430. Rissetto KC, Rindt H, Selting KA, et al. Cloning and
expression of canine CD25 for validation of an anti-human
CD25 antibody to compare T regulatory lymphocytes in healthy
dogs and dogs with osteosarcoma. Vet Immunol Immunopathol
2010;135:137–145.
431. Horiuchi Y, Tominaga M, Ichikawa M, et al. Relation-
ship between regulatory and type 1 T cells in dogs with oral
malignant melanoma. Microbiol Immunol 2010;54:152–159.
432. Pinheiro D, Singh Y, Grant CR, et al. Phenotypic and
functional characterization of a CD4+ CD25high FOXP3high regu-
latory T-cell population in the dog. Immunology 2011;132:111–
122.
433. Burton JH, Mitchell L, Thamm DH, et al. Low-dose
cyclophosphamide selectively decreases regulatory T cells and
inhibits angiogenesis in dogs with soft tissue sarcoma. J Vet
Intern Med 2011;25:920–926.
434. Kaser T, Gerner W, Hammer SE, et al. Detection of
Foxp3 protein expression in porcine T lymphocytes. Vet Immu-
nol Immunopathol 2008;125:92–101.
435. Kaser T, Gerner W, Hammer SE, et al. Phenotypic and
functional characterisation of porcine CD4+CD25high regulatory
T cells. Vet Immunol Immunopathol 2008;122:153–158.
436. Bolzer K, Kaser T, Saalmuller A, et al. Molecular char-
acterisation of porcine Forkhead-box p3 (Foxp3). Vet Immunol
Immunopathol 2009;132:275–281.
437. Wongyanin P, Buranapraditkun S, Chokeshai-Usaha K,
et al. Induction of inducible CD4+CD25+Foxp3+ regulatory T
lymphocytes by porcine reproductive and respiratory syndrome
virus (PRRSV). Vet Immunol Immunopathol 2010;133:170–182.
438. Silva-Campa E, Flores-Mendoza L, Resendiz M, et al.
Induction of T helper 3 regulatory cells by dendritic cells infected
with porcine reproductive and respiratory syndrome virus. Virol-
ogy 2009;387:373–379.
439. Dawson H, Solano-Aguilar G, Beal M, et al. Localized
Th1-, Th2-, T regulatory cell-, and inflammation-associated hepatic
and pulmonary immune responses in Ascaris suum-infected swine
are increased by retinoic acid. Infect Immun 2009;77:2576–2587.
440. Pilon C, Meurens F, Dauba A, et al. Induction of por-
cine regulatory cells by mycophenolic acid-treated dendritic cells.
Transplant Proc 2009;41:700–702.
441. Kaser T, Gerner W, Mair K, et al. Current knowledge
on porcine regulatory T cells. Vet Immunol Immunopathol 2011;
http://doi.org/10.1016/j.vetimm.2011.05.035 (in press).
442. Kaser T, Gerner W, Saalmuller A. Porcine regulatory T
cells: Mechanisms and T-cell targets of suppression. Dev Comp
Immunol 2011;35:1166–1172.
443. Gerner W, Stadler M, Hammer SE, et al. Sensitive detec-
tion of Foxp3 expression in bovine lymphocytes by flow cytome-
try. Vet Immunol Immunopathol 2010;138:154–158.
444. Hoek A, Rutten VP, Kool J, et al. Subpopulations of
bovine WC1+ gammadelta T cells rather than CD4+CD25high
Foxp3+ T cells act as immune regulatory cells ex vivo. Vet Res
2009;40:6.
445. Seo KS, Davis WC, Hamilton MJ, et al. Development of
monoclonal antibodies to detect bovine FOXP3 in PBMCs
exposed to a staphylococcal superantigen. Vet Immunol Immu-
nopathol 2009;128:30–36.
446. de Almeida DE, Colvin CJ, Coussens PM. Antigen-spe-
cific regulatory T cells in bovine paratuberculosis. Vet Immunol
Immunopathol 2008;125:234–245.
447. McNeilly TN, McIntyre J, Frew D, et al. Infestation of
sheep with Psoroptes ovis, the sheep scab mite, results in recruit-
ment of Foxp3(+) T cells into the dermis. Parasite Immunol
2010;32:361–369.
448. Rocchi MS, Wattegedera SR, Frew D, et al. Identifica-
tion of CD4(+)CD25(high) Foxp3(+) T cells in ovine peripheral
blood. Vet Immunol Immunopathol 2011;144:172–177.
449. Wagner B, Hillegas JM, Brinker DR, et al. Characteriza-
tion of monoclonal antibodies to equine interleukin-10 and detec-
tion of T regulatory 1 cells in horses. Vet Immunol
Immunopathol 2008;122:57–64.
450. Hamza E, Torsteinsdottir S, Eydal M, et al. Increased
IL-4 and decreased regulatory cytokine production following
relocation of Icelandic horses from a high to low endoparasite
environment. Vet Immunol Immunopathol 2010;133:40–50.
451. Hamza E, Steinbach F, Marti E. CD4+CD25+ T cells
expressing FoxP3 in Icelandic horses affected with insect bite
hypersensitivity. Vet Immunol Immunopathol 2011;http://doi.
org/10.1016/j.vetimm.2011.05.033 (in press).
452. Wagner B, Burton A, Ainsworth D. Interferon-gamma,
interleukin-4 and interleukin-10 production by T helper cells
reveals intact Th1 and regulatory TR1 cell activation and a delay
of the Th2 cell response in equine neonates and foals. Vet Res
2010;41:47.
453. Heimann M, Janda J, Sigurdardottir OG, et al. Skin-
infiltrating T cells and cytokine expression in Icelandic horses
affected with insect bite hypersensitivity: A possible role for
regulatory T cells. Vet Immunol Immunopathol 2011;140:63–
74.
454. Robbin MG, Wagner B, Noronha LE, et al. Subpopula-
tions of equine blood lymphocytes expressing regulatory T cell
markers. Vet Immunol Immunopathol 2011;140:90–101.
455. Langier S, Sade K, Kivity S. Regulatory T cells: The sup-
pressor arm of the immune system. Autoimmun Rev 2010;10:
112–115.
456. Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T
cells: How do they suppress immune responses? Int Immunol
2009;21:1105–1111.
457. Workman CJ, Szymczak-Workman AL, Collison LW,
et al. The development and function of regulatory T cells. Cell
Mol Life Sci 2009;66:2603–2622.
458. Rudensky AY. Regulatory T cells and Foxp3. Immunol
Rev 2011;241:260–268.
459. Campbell DJ, Ziegler SF. FOXP3 modifies the pheno-
typic and functional properties of regulatory T cells. Nat Rev
Immunol 2007;7:305–310.
460. Shalev I, Schmelzle M, Robson SC, et al. Making sense
of regulatory T cell suppressive function. Semin Immunol
2011;23:282–292.
461. Wan YY. Regulatory T cells: Immune suppression and
beyond. Cell Mol Immunol 2010;7:204–210.
462. Caramalho I, Lopes-Carvalho T, Ostler D, et al. Regula-
tory T cells selectively express Toll-like receptors and are acti-
vated by lipopolysaccharide. J Exp Med 2003;197:403–411.
463. Dai J, Liu B, Li Z. Regulatory T cells and Toll-like
receptors: What is the missing link? Int Immunopharmacol
2009;9:528–533.
464. Liu H, Komai-Koma M, Xu D, et al. Toll-like receptor
2 signaling modulates the functions of CD4+CD25+ regulatory T
cells. Proc Natl Acad Sci USA 2006;103:7048–7053.
Immunopathology of Sepsis 481
465. Nyirenda MH, O’Brien K, Sanvito L, et al. Modulation
of regulatory T cells in health and disease: Role of toll-like recep-
tors. Inflamm Allergy Drug Targets 2009;8:124–129.
466. Monneret G, Debard AL, Venet F, et al. Marked elevation
of human circulating CD4+ CD25+ regulatory T cells in sepsis-
induced immunoparalysis. Crit CareMed 2003;31:2068–2071.
467. Saito K, Wagatsuma T, Toyama H, et al. Sepsis is char-
acterized by the increases in percentages of circulating
CD4+ CD25+ regulatory T cells and plasma levels of soluble
CD25. Tohoku J Exp Med 2008;216:61–68.
468. Venet F, Chung CS, Kherouf H, et al. Increased circulat-
ing regulatory T cells (CD4+CD25+CD127-) contribute to lym-
phocyte anergy in septic shock patients. Intensive Care Med
2009;35:678–686.
469. Venet F, Pachot A, Debard AL, et al. Increased percent-
age of CD4+ CD25+ regulatory T cells during septic shock is due
to the decrease of CD4+CD25- lymphocytes. Crit Care Med
2004;32:2329–2331.
470. Heuer JG, Zhang T, Zhao J, et al. Adoptive transfer of
in vitro-stimulated CD4+ CD25+ regulatory T cells increases bac-
terial clearance and improves survival in polymicrobial sepsis. J
Immunol 2005;174:7141–7146.
471. Scumpia PO, Delano MJ, Kelly KM, et al. Increased
natural CD4+ CD25+ regulatory T cells and their suppressor
activity do not contribute to mortality in murine polymicrobial
sepsis. J Immunol 2006;177:7943–7949.
472. Wisnoski N, Chung CS, Chen Y, et al. The contribution
of CD4+ CD25+ T-regulatory-cells to immune suppression in sep-
sis. Shock 2007;27:251–257.
473. Tiemessen MM, Jagger AL, Evans HG, et al.
CD4+ CD25+ Foxp3+ regulatory T cells induce alternative activa-
tion of human monocytes/macrophages. Proc Natl Acad Sci USA
2007;104:19446–19451.
474. Venet F, Pachot A, Debard AL, et al. Human
CD4+ CD25+ regulatory T lymphocytes inhibit lipopolysaccha-
ride-induced monocyte survival through a Fas/Fas ligand-depen-
dent mechanism. J Immunol 2006;177:6540–6547.
475. Hodge G, Scott J, Osborn M, et al. Increased T regula-
tory cells and decreased Th1 pro-inflammatory cytokines corre-
late with culture-positive infection in febrile neutropenia
childhood oncology patients. Cytokine 2011;53:286–288.
476. Huang LF, Yao YM, Dong N, et al. Association
between regulatory T cell activity and sepsis and outcome of
severely burned patients: a prospective, observational study. Crit
Care 2010;14:R3.
477. Hein F, Massin F, Cravoisy-Popovic A, et al. The rela-
tionship between CD4+ CD25+CD127- regulatory T cells and
inflammatory response and outcome during shock states. Crit
Care 2010;14:R19.
478. van Maren WW, Jacobs JF, de Vries IJ, et al. Toll-like
receptor signalling on Tregs: To suppress or not to suppress?
Immunology 2008;124:445–452.
479. Walker LS. Regulatory T cells overturned: The effectors
fight back. Immunology 2009;126:466–474.
480. Marshall JC. Sepsis: Rethinking the approach to clinical
research. J Leukoc Biol 2008;83:471–482.
481. Girbes AR, Beishuizen A, Strack van Schijndel RJ. Phar-
macological treatment of sepsis. Fundam Clin Pharmacol
2008;22:355–361.
482. Wittebole X, Collienne C, Castanares-Zapatero D, et al.
Adjunctive therapies for severe sepsis. Int J Antimicrob Agents
2008;32(Suppl 1):S34–S38.
482 Lewis et al
